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vAbstract
Cancer is a genetic disease and historically the discovery of underlying
genetic alterations has been critical to our understanding of disease and past
treatment successes. However, cancer still poses an important health threat
and most available drugs are not capable of providing complete remission.
Drug targets are typically proteins, but are based on genetic findings. Thus
studying cancer systems at the level of proteins and their signaling can pro-
vide the additional level of data needed for the development of eﬀective drugs.
This thesis summarizes the work undertaken during my doctoral studies in
an eﬀort to contribute to the study of signaling dynamics in cancer systems.
This thesis is divided into two parts. Part I begins with a brief intro-
duction in the use of omics in systems cancer research with a focus on mass
spectrometry as a means to quantitatively measure protein and signaling
dynamics in the identified protein networks (Chapter 1). Gene fusions are
portrayed in-depth as an example of a major genetic alteration found to
occur in a variety of cancers, the most infamous of which has lead to the
development of the specific tyrosine kinase inhibitor imatinib and a major
success in the treatment of chronic myelogenous leukemia. However, this
is the exception rather than the norm as most drugs are developed based
on genetic findings while designed to act on the protein level, and might
contribute to explaining the paucity of specific eﬀective cancer therapeutics
available. Furthermore, this underlines the importance of proteomic studies
and the conclusions drawn for the high-throughput data generated in the
latter. Chapter 2 gives a temporal overview of precision gene-editing in the
context of systems biology. Following the past successes of methods such
as zinc-finger nucleases and TALEs, the novel CRISPR-Cas technology has
rapidly become an extremely popular gene-editing tool. Its mechanism of
action, several applications and potential shortcomings are discussed. The
Chapter is concluded with a final application: chromosomal translocations
can be generated in vitro or in vivo using nuclease-based targeted gene-
editing. Part II illustrates the use of mass spectrometry-based proteomics
and phospho-proteomics in studying the eﬀects of perturbations at the cel-
lular level. Chapter three captures the very early signaling dynamics related
to cell migration following wounding in triple negative breast cancer cells,
and their potential role as novel targets for therapies aimed at reducing the
metastases. Chapter four describes the induction of the oncogenic chimeric
gene PRKAR1A-RET in thyroid cells. Its transformative potential is shown
and the ensuing changes are measured at the protein and signaling levels.
This study demonstrates the use of the novel CRISPR-Cas technology for
the generation of chromosomal rearrangements in vitro and investigates the
eﬀects of this important genetic aberration in a physiologically relevant cel-
lular setting. Part III concludes the thesis by providing a global discussion
and future perspectives for the studies presented in part II.
Overall, the work presented herein aims to underscore the importance of
studying cancer systems at the protein level, the dynamics of which define
phenotypic outcome. The eﬀects of cellular and genetic perturbations at the
protein network level were studied using mass spectrometry-based proteomics
vi
and, the results whereof suggest interesting avenues for future development
of cancer therapies.
vii
Dansk Resume
Cancer er en genetisk sygdom og historisk set har kortlægningen af de
underliggende genetiske ændringer været central for vores forståelse af syg-
dommen og grundlaget for tidligere behandlingsformer’s succes. Alligevel er
cancer til stadighed en stor sundhedstrussel. De fleste behandlingsstrate-
gier er ikke i stand til fuldt at helbrede patienter. Medicinsk behandling er
typisk målrettet proteiner, men forskningen bag dem er baseret pågenetiske
opdagelser. Et nyt domæne af viden kan bidrage til ny eﬀektiv medicin ved
direkte at studere cancersystemer med udgangspunkt i proteiner og deres sig-
nalering. denne afhandling opsummerer mit Ph.d. arbejde, og har til hensigt
at bidrage til forståelsen af signalering i dynamiske cancersystemer.
denne afhandling er opdelt i to. Del I begynder med en kort intro-
duktion til anvendelsen af ’omics’ i systembiologisk cancerforskning. Her
vil jeg fokusere påmassespektroskopi som kvantitativ målemetode af pro-
teiner og signaleringsdynamikker i identificerede protein netværk (kapitel
1). Genfusioner bliver grundigt beskrevet, som et eksempel påen voldsom
genetisk modifikation. De findes i en lang række af cancertyper, hvor iblandt
opdagelsen af den mest kendte genfusion har ført til udviklingen en specifik
tyrosin kinase inhibitor, Imatinib, og herfra en stor forbedring i behandlin-
gen af kronisk myeloid leukæmi. Imatinib er dog undtagelsen der bekræfter
reglen, da det meste medicin er udviklet fra genetisk viden, men designet til
at virke pået proteinniveau, hvilket muligvis forklarer den nuværende man-
gel påeﬀektive cancer behandlingsformer. Dette understreger betydningen
af proteomiske studier og de konklusioner der drages fra den store mængde
viden der generes i disse. Kaptiel to giver et overblik i tid, af præcis genma-
nipulering i den systembiologiske kontekst. I kølvandet påtidligere succes-
fulde teknikker, som zinc-finger nukleaser og TALEs, er den nye CRISPR-
Cas teknologi hurtigt blevet en ekstremt populært værktøj til genmodifi-
cering. Dets virkningsmekanisme, forskellige anvendelser og potentielle be-
grænsninger beskrives. Kapitlet afrundes med en anvendelse: kromosomal
translokationer kan genereres in vitro eller in vivo vha. målrettede nuklease-
genmanipulering. Del II illustrerer brugen af massespektroskopi og phospho-
proteomik i studiet af perturbationer pådet cellulære niveau. Kapitel tre
beskrives de meget tidlige signal-dynamikker relateret til migration som følge
af sår-ridsning i triple negativ brystkræft, og deres potentielle rolle som nye
mål for behandlinger der er skal reducerer metastaser. Kapitel fire beskriver
det onkogenske kimære gen PRKAR1A-RET i celler fra skjoldbruskkirtlen.
Dets transformative potentiale vises og de efterfølgende virkning påprotein-
og signaleringsniveau måles. Dette studie demonstrerer brugen af den nye
CRISPR-Cas teknologi i skabelsen af kromosomale omrokeringer in vitro og
undersøger eﬀekten af denne betydningsfulde genetiske afvigelse i en fysiol-
ogisk relevant cellulær kontekst. Del III opsamler specialet med en generel
diskussion og præsenterer fremtidige perspektiver for arbejdet i del II.
Alt i alt er målet med det fremlagte arbejde at understrege vigtighe-
den af at studere cancersystemer fra et protein-perspektiv, hvis dynamikker
bestemmer det fænotypeiske udtryk. Konsekvensen af cellulære og genetiske
viii
perturbationer påcellens proteiner blev studeret med proteomik baseret på-
massespektroskopi og resultaterne herfra antyder nye interessante muligheder
for fremtidig udvikling af behandlingsstrategier mod cancer.
ix
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1Part I
Introduction

3The first part of this thesis aims to provide a brief introduction to the
use of high-throughput technologies in cancer research since the advent of
sequencing, with a focus on genomics and proteomics. These technologies
are characterized by their ability to generate data in a high-throughput fash-
ion and as a consequence of the breadth of data generated, allow global,
systematic studies that were previously diﬃcult to conduct. After a succint
overview of these large-scale studies within cancer research, two diﬀerent
ways of perturbing the cellular protein network are outlined. The first is
by creating a direct perturbation at the level of the cell’s signaling network.
The second is a genetic pertubation. Indeed, chromosomal rearrangements
are introduced as an example of the genetic basis of cancer for which targeted
therapy exists in the form of a kinase inhibitor, as it around these that a large
part of the work carried out in this thesis is centered. The nature and im-
portance of chromosomal rearrangements, a genetic perturbation to the cell,
are discussed in detail. Furthermore, the current standard workflow in terms
of integration of data sets with the hope of developing novel therapeutic
strategies is outlined. Building on the topic of chromosomal rearrangements,
chapter 2 is a published book chapter which provides a historical perspective
on gene editing and the popular CRISPR-Cas system, setting the stage for
the use of this powerful technology to generate and study gene fusions.

5Chapter 1
Investigating cancer signaling
using mass spectrometry-based
proteomics
1.1 Cancer
Despite ancient civilizations already being confronted with cancer [1], we
continue to struggle to understand and most importantly, to develop eﬀective
means to treat it. The World Health Organization (WHO) reported cancer
to be the second leading cause of death worldwide, with a death toll of 8.8
million in 2015 [2]. The incidence of cancer continues to rise, being the
highest in high-income countries in Western Europe, North America, Japan,
the Republic of Korea, Australia and New Zealand. This can be attributed
to advances in general medicine which have led to longer life expectancy,
thus resulting in a higher number of incident cases due to cancer’s strong
relationship with age. This improvement in longevity in addition to increased
exposure to known carcinogens such as tobacco or UV radiation has led to
cancer topping the list of causes of mortality globally.
1.1.1 Cancer: a disease of networks
Major biological events such as cell division or migration involve both intra-
and inter-cellular interactions and the organization of these networks of cells
paints a complex picture of synergy between various cellular components,
such as genes, proteins, and metabolites. Indeed, signaling networks have
evolved such that cells can integrate multiple input cues in order to collec-
tively respond to changes in the environment. With this in mind, the central
dogma of biology describing the flow of genetic information from DNA to
proteins via messenger RNA can no longer be viewed in a strictly linear
fashion nor at the level of a single gene [3]. Instead the large number of
cellular players should be considered as constituting a connected network
and participating in dynamic and non-linear processes, with features such as
feedback and crosstalk [4].
The undertaking of the human genome project in the ’90s helped bring
about the latter holistic description of biological systems. It also spurred the
development of novel high-throughput technologies such as mass spectrom-
etry applied to the large-scale study of proteins, which will be discussed in
section 1.4.2. The field of systems biology employs these technologies and
develops models aiming to describe how the parts of a network give rise to
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the behavior of the system as a whole [4]. A biological system generally ex-
hibits emergent features that would not be apparent when investigating its
individual parts. The former "reductionist" approach has successfully inven-
toried the majority of the cellular players and many of their interactions, but
has failed to provide a working model of how properties specific to systems
arise. With the continued improvement of instrumentation and development
of novel technologies, large lists of genes, transcripts, metabolites, proteins
and more have been generated, and the focus has shifted toward a global
quantitative view of the biological system at hand, rather than an isolated
gene or pathway [5]. These technologies have been used to better under-
stand events occurring within the cell, such as determining breast cancer
biomarkers from system-wide protein-protein interaction data [6].
This approach has given weight to the belief that in order to understand
complex biological systems, questions require a multi-pronged approach with
data representing the multiple layers of complexity. Given the biological
layers of DNA transcription into RNA, followed by mRNA translation leading
to protein expression, and finally post-translational modification of proteins,
technologies such as genomics, transcriptomics, metabolomics, epigenetics
and proteomics, as well as phenotypic data from imaging should be used in
concert and modeled to produce a more complete snapshot of the process of
interest. The emergence of technologies capable of acquiring data at a high
throughput such as deep sequencing and quantitative mass spectrometry-
based proteomics enable these approaches.
Uncontrolled proliferation and metastases are just two of the most promi-
nent characteristics of cancerous cells that have been discovered by scientific
advances in recent decades. Progress in the clinic has been furthered with the
development of chemotherapeutics to treat patients suﬀering from cancer or
to alleviate symptoms and thereby improve life expectancy. Drugs developed
to address these characteristics typically possess a substantial level of toxi-
city for the patient, since the uncontrolled processes are relevant in healthy
individuals and it is thus diﬃcult to target only the malignant cells. More re-
cently, the genomic revolution (and the sequencing of the full human genome
[7]–[9] triggered by easier access to DNA sequencing technology as well as
reduced cost has enabled many studies aiming to identify the major genetic
players in the onset and progression of cancer.
As a result of a large number of sequencing studies (described in more de-
tail in section 1.1.2), countless genomic modifications such as single-nucleotide
polymorphisms, deletions and frameshifts are being identified in cancer genomes.
In fact, chromosomal aberrations such as insertions, deletions, or transloca-
tions require genetic technologies in order to be identified during patient
tumor profiling.
While cancer has historically been considered a genetic disease and the
detection of genetic aberrations is crucial to our understanding of disease,
these alterations alone do not provide complete insight into the question of
how cells become cancerous. Indeed, cancer has emerged as a multi-faceted
disease with genetic mutations, regulation by epigenetic markers [10], and
dysregulation of core cellular processes such as proliferation, migration and
homeostasis relying on signaling and interactions at the protein level [11].
Due to underlying genetic alterations cancer cells respond diﬀerently to the
input cues received from the environment compared to healthy cells. This
allows malignant cells to bypass the normally tightly regulated collective cell
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population dynamics and instead make decisions purely for their own benefit,
resulting for instance in uncontrolled proliferation.
In an attempt to rationalize the complex phenomena underlying tumor
growth and metastatic dissemination, Hanahan and Weinberg proposed the
now well-known "hallmarks of cancer" in 2000 [11]. This view presented
a framework governing the transformation from a normal to disease state,
which occurs by successive acquisition of hallmark properties. Rather than
each cancer being considered a separate disease, the hallmarks aim to delin-
eate the diﬀerences between healthy and cancerous cells. This cancer systems
hypothesis has since been expanded to encompass advances in research [12],
eﬀectively further displaying the complexity of the disease.
In many cases the functionality of genetic aberrations remains unknown.
Rather than attempting to map each of these genetic anomalies to a specific
deregulated oncogene or tumor suppressor gene, the shared hallmark charac-
teristics suggest a convergence of these many varied mutational profiles into a
less complex phenotypic space, governed by fewer underlying principles [13].
Given that proteins are the mediators of cellular response to genetic cues,
and thus one step closer to the observed phenotype, the complexity at the
protein level might also be expected to be less than that at the genetic level
[14].
Practically speaking, approaching these characteristics is typically done
by studying the pathways associated with particular cellular processes. A dis-
crete number of pathways can serve as an organizing principle with respect
to the many players in the proteome. Indeed, thousands of mutations can be
detected in a single tumor sample [15] and can be mapped to a far smaller
number of processes, of the order of tens [16]. This linear paradigm appeals
due to its simplicity but also in particular since pathways are by definition
composed of many components, providing multiple targets for drug develop-
ment rather than needing to target a single oncogene or tumor-suppressor
related to a genetic defect. However, due to the complexity of interactions
among the diﬀerent components (e.g. cross-talk, feedback mechanisms), the
consequences of targeting various nodes are not equivalent (Fig. 1.1, taken
from [17]).
In order to understand how cancerous cells decipher and process internal
and external signals as well as to elucidate the mechanisms behind phe-
nomena such as resistance or metastasis, it is critical to understand how
to interpret the various omics datasets together in order to gain a deeper
understanding of these complex processes. This begins perhaps with the
profiling of patient tissue samples and cell lines using deep sequencing and
proteomics to understand the relationships between gene-level perturbations
and protein-level phenotype.
1.1.2 Large-scale studies in cancer research
As mentioned earlier, the genomics field has seen the development of high-
throughput next generation sequencing technologies such as whole exome
sequencing (WES), whole genome sequencing (WGS), RNA-seq and ChIP-
seq arrays over the past two decades which have been critical in providing
genome-wide data and thus in shifting toward systematic analyses. Although
genome-wide association studies (GWAS) - the detection of SNPs associated
with a phenotypic trait - have identified numerous relevant genes as being
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Figure 1.1: Depiction of the eﬀect of environmental con-
text on the various levels of biological regulation and how
these interact toward a cell or tissue phenotype. Environ-
mental context can intervene at the genetic, transcriptional,
translational and post-translational levels. The protein level
(both in terms of concentration as well as post-translational
modifications can be considered to convey the eﬀective result
of the cumulative regulatory levels and is the most proximal
to phenotypic behavior, thus justifying its quantification as
a readout of cellular processes.
linked to investigated traits, they still fail to explain much of the diversity in
genetic traits, such as height as well as in common complex diseases such as
cardiovascular disease or diabetes.
In an attempt to make sense of the immense amount of sequencing data,
the passenger-driver paradigm emerged as providing a way to classify cancer-
related mutations. Driver mutations are those conferring a growth advantage
to a cell and thus critical to malignancy. Passenger mutations represent
those that occur as a result of the genomic instability in cancer cells. These
passenger mutations were considered not to augment the fitness advantage of
a cell and thus have no eﬀect [18]. Within this paradigm, GWA studies were
expected to uncover associations between SNPs and the cancerous phenotype,
where a small number of driver mutations stand out as the main culprit. The
identified genes linked to cancer would in turn determine novel treatment
avenues. This approach has been successful in certain cases. For instance,
the identification of a mutation in complement factor H in a study focused
on macular degeneration linked inflammation to this disease, and targeting
this pathway has shown therapeutic success [19]. However, for the most part
it has become apparent that cancer is driven not by a single mutation but
is likely the result of a larger number of mutations. Furthermore, even the
same mutation may have diﬀerent phenotypic outcomes depending on the
state of the network the expressed protein resides in [20]. Indeed, there are
several limitations concerning GWA studies, one of which is the diﬃculty
in detecting low frequency mutations, which comprise the majority of the
cancer landscape [21].
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With this in mind and taking into account once again the broad variety
of cellular processes that cancer impacts, several large-scale consortia such as
The Cancer Genome Atlas (TCGA) and International Cancer Genome Con-
sortium (ICGC) have led eﬀorts to sequence and characterize the genomes of
cancerous cells and tissues using a multi-platform approach: whole genome
sequencing, miRNA expression, RNA-seq, and DNA copy number variation
[22], [23]. TCGA thus provided the first large scale integrative view of the ge-
netic landscape of ovarian cancer, identifying mutated genes and suggesting
diﬀering therapeutic strategies depending on disease subtype, or "subtype-
stratified care".
The many genomic and transcriptomic eﬀorts to sequence cancer sys-
tems have shown that mutations leading to loss-of-function are more preva-
lent than those related to gain-of-function [24], the latter being the ones for
which a drug may be developed (e.g. kinase inhibitors such as imatinib, er-
lotinib, etc.). Therefore, the number of therapeutic directions that can be
explored based on genetic mutational profiles is limited. Moreover, the ma-
jority of mutations are found in non-coding regions, the functional eﬀects of
which remain poorly understood. Both of these findings support the need
for integrating information at both the genetic and proteomic level in order
to identify therapeutic targets.
Genomic data is typically projected onto known interaction maps and
functional conclusions are made based on this information. While this back-
ground data might be true in the context in which it was generated, it does
not necessarily reflect the context of another cancer cell, let alone a tumor.
It is therefore also critical to stress the relevance of matched genetic and phe-
notypic data, which is where modern proteomics takes on an important role.
Computational platforms such as ReKINect [25] bring together genomics and
signaling networks in an eﬀort to identify mutations causing rewiring of net-
work dynamics and thus providing functional information associated with
these mutations.
1.2 Signaling networks as drug targets ?
While the importance of a comprehensive catalog of the genetic basis of can-
cers should not be dismissed, it is questionable how much it will contribute in
terms of therapeutic advance. The outcome of these datasets is the sugges-
tion of therapeutic targets based on deregulated genes which for the majority
are already known [14]. However, the targets of drugs are typically proteins
and it is signal transduction proteins that are behind the cancer phenotype
we observe and the associated malignant behavior. Methods for the treat-
ment of cancer (excluding surgery) can be classified grossly into the following
categories: chemotherapy, radiotherapy, targeting oncogenes, targeting pro-
cesses harnessed by cancer cells (e.g. angiogenesis), or immunotherapy (most
recently, CAR T-cell therapy). Chemotherapy and radiotherapy both target
cells with increased replication, but cause severe adverse eﬀects as they are
non-specific, targeting even healthy cells that are dividing. This is not the
case for drugs aimed at interfering with oncogenes. Indeed, kinase-specific
drugs such as imatinib (specific to the tyrosine kinase domain of abl) or
trastuzumab (targeting ErbB2 in breast cancer cells) have been successful in
the clinic, even though in the long-term many patients face relapse due to
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resistance to the inhbitors. If the aim based on genetics is to design novel
drugs based on targets rather than on phenotypic outcome, then there is an
additional biological layer separating these data and drug targets, the eﬀects
of which need to be taken into account. Indeed, as mentioned above, the cor-
relation of mRNA levels and protein is far from perfect (Pearson correlation
coeﬃcients in the literature range from approximately 0.5 to 0.7) thus sug-
gesting a supplementary layer of regulation that is not yet fully understood.
The work described in Chapter 4 attempts to link the migratory pheno-
type of triple negative breast cancer cells to signaling occurring as a response
to a wounding, a "signaling perturbation" rather than a genetic perturbation,
as is the case in Chapter 3. The signaling we identify may provide additional
avenues for the development of cancer therapeutics and will be discussed in
more detail in Chapter 4. During this work the lack of known functionally
annotated phosphorylation sites was striking and suggests that there is much
to be discovered regarding the functional roles of phosphorylated sites.
1.3 Chromosomal rearrangements in cancer
With the advent of the genomic revolution the landscapes of genomic al-
terations became increasing well-characterized, and the mass of data gen-
erated due to the large number of identified aberrations uncovered meant
that system-wide questions could be addressed (see GWAS studies in section
1.1.2). Examples of point mutations associated with malignancy are BRAF
V600E, as well as mutations in p53 and in src. Next-generation sequencing
allows the identification of genomic modifications such as single-nucleotide
polymorphisms, small insertions and deletions. The more recent develop-
ment of RNA-seq has exposed the frequency of chromosomal aberrations
across many tissue and cancer types [26], and their potential as oncogenes
and possible drug targets has emerged. The following subsections provide an
introduction to chromosomal rearrangements, their oncogenic potential and
their impact on protein signaling networks, and thus why more attention
should be given to their role in cancer.
1.3.1 The Philadelphia chromosome
In the early 20th century Theodor Boveri proposed that chromosomal ab-
normalities seen in tumor tissues were the cause of transformation toward
malignant entities, thereby linking genes with cancer [27]–[29]. Only in 1959
did the Philadelphia case (the fusion of BCR and ABL1) become the first
chromosomal aberration to be consistently associated with a human disease:
the hallmark of chronic myelogenous leukemia (CML) is now known to be
the t(9;22)(q34;q11) chromosomal translocation [30]. It is now indeed widely
known that chromosomal aberrations and impaired DNA damage repair ap-
paratus are critical in tumor initiation and progression, thereby linking ge-
netics to phenotype [31], [32]. The BCR-ABL rearrangement provides an
ideal example of a driver for cancer based on a genomic alteration, which
has spurred the development of the first targeted kinase inhibitor for the
treatment of CML.
The BCR-ABL1 gene fusion (the result of which is also known as the
Philadelphia chromosome) has been identified in three diﬀerent forms, as-
sociated with diﬀerent forms of leukemia depending on the precise location
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Figure 1.2: Image taken from Greuber et al.. Illustration
of the diverse ABL1 and ABL2 fusion proteins resulting from
chromosome translocations with various partner genes, and
leading to various pathological phenotypes.
of the breakpoint : P210 BCR-ABL1 as a marker of CML [33]; P190 BCR-
ABL1 (also known as p185) in many cases of adult and childhood B cell acute
lymphocytic leukemia (ALL and B-ALL, respectively) [34], [35]; and P230
BCR-ABL1 in neutrophilic CML and CML [36], [37]. The exact location of
the breakpoint results in diﬀerent response to chemotherapy, e.g. patients
harboring the p210 isoform respond well to treatment whereas others develop
resistance to tyrosine kinase inhibitors. Several kinase inhibitors have been
developed targeting the tyrosine kinase function of ABL1, notably imatinib
(Gleevec; Novartis), dasatinib (Sprycel; Bristol-Myers Squibb) and nilotinib
(Tasinga; Novartis). Imatinib has been amongst the more successful treat-
ments of chronic phase CML and exerts its eﬀect as an ATP competitor, but
up to a third of patients develop resistance due to point mutations in the
kinase domain of the BCR-ABL1 complex [38]. Moreover, the drug is less ef-
fective for patients presenting with alternative BCR-ABL fusions. Strategies
to combat resistance to these drugs has been to target key proteins down-
stream of BCR-ABL [39]. Moreover, ABL has been identified as a fusion
partner with a number of other genes, and associated with diﬀerent clinical
outcomes (Fig. 1.2).
1.3.2 A focus on the role of tyrosine kinases as translocation
partners
Many of the well-characterized fusion genes have been identified as involved
in leukemic malignancies. This could be due to the amenability of leukemic
samples and cell lines, as well as a lack of systematic cytogenetic analysis.
Fusions have also been identified in solid tumors, albeit at a lower rate. In
particular, a non-negligible number of human kinase genes in leukemic as
well as solid tumors have been found to be rearranged and involved in cancer
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Figure 1.3: Image taken from Stransky et al.. Depiction
of the recurrent kinase fusions arising in various solid tumor
types. Thyroid carcinoma (leftmost) is the tissue type for
which the highest percentage of (TCGA) patient samples
contain a kinase rearrangement (bar plot). The color coding
indicates the type of fusion depending on its recurrence as
well as previous knowledge of the kinase fusion partner.
(Fig. 1.3) [26], [40], [41]. Moreover, the drug design strategy that led to
the development of successes such as imatinib and dasatinib have inspired
small molecule compounds with promising results for solid-tumor cancers,
e.g. crizotinib for ALK raerrangements [42], [43].
Trends in the association of two partner genes and the types of aberrant
behavior they result in have been found when comparing several kinase fu-
sions [41]. In most fusion proteins with a functional kinase domain, the latter
is located C-terminally and inhibitory elements have a tendency to be found
at the N-terminus. In order to retain kinase activity, the intact C-terminal
kinase domain is conserved and the partner gene nearly always supplants the
N-terminal portion of the kinase protein. In the case of fusions where one
partner is a receptor tyrosine kinase (RTK), the extracellular ligand-binding
domain originally belonging to the RTK is thus often lost in the final fu-
sion product. This is also the case for the inhibitory domains found in most
tyrosine kinases (TK), which stabilize the inactive kinase conformation and
thereby dampen activity when stimuli is absent. This pattern generally re-
sults in the expression of the fusion protein being driven by the promoter of
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the 5’ partner gene, the latter is also often critical for controlling oligomer-
ization and thus activation of the kinase domains. This may lead to cases
where the kinase domain becomes constitutively active in a cell positive for
the translocation, whereas the same cell type without the rearrangement may
display low or no expression of the wild-type kinase under normal conditions
[44]. For instance, upon induction of BCR-ABL expression in mice CML oc-
curred only if the expression was induced specifically in haematopoietic stem
cells. A BCR-ABL fusion gene under the control of a diﬀerent promoter
generated other types of neoplasms [40], [45], [46].
There are several ways in which the kinase moiety can be deregulated in
the context of chromosomal rearrangements. Activation of tyrosine kinase
domains within fusion products can occur if the partner gene expresses mul-
timerization domains, thereby bringing kinase domains into proximity and
mimicking RTK activation, e.g. the PNT domain of ETV6, which associates
with ABL, PDGFRB, JAK2, and TRKC [47]–[50]. Coiled-coil domains ap-
pear to be most frequently used to drive oligomerization in TK fusions (60%
of tyrosine kinases harbor a coiled-coil domain, vs. 9% in the entire human
proteome) [41], however a number of oligomerization domains have been de-
tected in unique fusions. Furthermore, the degree of oligomerization can
vary from dimers to polymeric structures [51]–[53] and it has been suggested
that not all forms possess transformative potential [49]. Deletion of the BCR-
ABL oligomerization domain was shown to severely limit the fusion product’s
tyrosine kinase activity and in vitro transformative capacity [54].
The partner gene can provide additional advantageous functionalities,
such as targeting the fusion product to the nuclear pore complex, recruiting
additional proteins resulting in a larger complex [55], recruiting chaperones
mediating protein stability [56], and the recruitment of the wild-type form
of the partner protein thereby exacerbating the eﬀect of the translocation.
As a consequence of these changes in the regulation of the kinase domains,
recurrent cancer-specific rearrangements drive the cell toward a diseased state
and provide it with a growth and proliferation advantage [57], [58] ultimately
leading to transformation, marking the transition from normal to malignant
cells.
1.3.3 Transforming capacity of fusion kinases
In 1988 Daley & Baltimore [59] showed that p210 bcr/abl was capable of
transforming hematopoietic cell types [46]. Similarly, in 2005 a study by
Warneret al. [60] demonstrated full leukemic conversion of normal human
hematopoietic cells by introduction of TLS-ERG using retroviral transduc-
tion techniques. This led to the spontaneous occurrence of further genetic and
epigenetic alterations, providing evidence for multiple cooperating events in
human leukemogenesis. Indeed, although the direct eﬀects of TLS-ERG ex-
pression alone were insuﬃcient to induce complete transformation, extended
culture of these cells resulted in the acquisition of additional changes and
gave rise to a fully transformed hematopoietic cell line from primary cells.
Interestingly, a requirement for maintenance of telomere activity emerged,
and was shown to be a critical second event following introduction of TLS-
ERG in order for cells to achieve full transformation (see Fig. 1.4) [60].
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Figure 1.4: Adapted from Warner et al.. TLS-ERG fusion
expressed in human cord blood cells, compared to "Neo"
negative control (no fusion). After a certain amount of time
in culture, the fusion-containing cells show increased prolif-
eration.
With this in mind it is interesting to note that Lundberg et al. (2002)
presented a new model facilitating the study of transforming events by im-
mortalization of a primary cell line by the successive introduction of SV40
early region and the telomerase catalytic subunit hTERT. Indeed, these cells
show prolonged proliferative potential however are not capable of forming
colonies in assays testing for anchorage independant growth [61] (Fig. 1.4).
In the case of BCR-ABL, the fusion has been shown to activate Ras via
diﬀerent mechanisms. In one scenario, the fusion kinase can be coupled to
the MAPK pathway, capable of transformation by activating Ras [62]. The
latter is frequently found mutated in tumors and disturbs the regulation of
core cellular processes such as proliferation and diﬀerentiation. In any case,
mitogenesis is induced by providing the cell with aberrant stimulation by
the TK, which replaces signaling that would normally be tightly regulated
by cytokine receptors [63]. Another example of cytokine signaling hijacking
are the STAT family proteins which are involved in the regulation of cell
cycle progression, where amongst others STAT5 has been shown to be acti-
vated following fusion tyrosine kinase (FTK) expression [64]. However, this
seems to depend on the exact translocation, since STAT5 is not essential for
transformation by BCR-ABL [65].
The replicative stress and genomic instability induced by the FK might
allow for the accumulation of secondary mutations necessary for disease pro-
gression. However as fusion genes can be detected in the DNA of healthy
patients, expression of the fusion itself may be insuﬃcient for transformation
and require additional mutations [66]. Another interesting point is whether
these secondary mutations are a direct consequence of fusion protein activity
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or arise due to the transformed state of the cell. Despite the evidence point-
ing toward the first situation [67]–[70], the number of genetic abnormalities
in CML cells are rather low implying that the BCR-ABL fusion protein itself
might not possess the anticipated mutagenic potential [44].
In normal cells apoptosis is triggered in response to DNA damage, provid-
ing a barrier to proliferation of cancerous cells. FKs allow cells to circumvent
this limitation by sending survival signals to block apoptosis [71]. BCR-ABL
was even shown to reverse the apoptotic process induced by cytokine depri-
vation, thereby enabling transformation [72].
Fully transformed cells show a disruption of DNA repair mechanisms,
thereby maintaining genomic instability which is thought to be involved in
the further progression of the disease to an advanced state [73]. Moreover, the
fusion kinase is thought to cause ‘oncogene addiction’ due to the suppression
of the apoptotic response ensuring further growth despite increased DNA
damage due to genomic instability. Oncogene addiction is the dependance
of a cancer cell on an oncogenic for its malignant properties, and targeting
this oncogene is a rationale for targeted therapy [74]. The PI3K pathway
is particularly interesting in this context as it is involved in both survival
and mitogenic signaling [75]. Some or all three of the MAP kinase pathways
(ERK, JNK, and p38) have been noted to be activated in fusion kinase-
transformed cells [76]–[78]. In contradiction, these pathways have also been
reported not to be activated for diﬀerent FTKs or to have opposite eﬀects in
diﬀerent cell types [79]–[81].
In conclusion, the cellular states critical for transformation as well as
the aftermath of transformation have been given much attention, however
the transformation event itself remains elusive. Induction of mitogenesis,
replicative stress, undermining of DNA repair and apoptosis are likely to be
the conditions critical for transformation, but the causality between them is
currently still unclear and, given the encouraging results common to several
FTKs, it is tempting to believe that a pattern will emerge from studying as
broad a panel of fusion kinases as possible. However, in light of the above
contradictions, careful selection of the appropriate model system (cell lines,
organ, tissue) will be critical to make biologically relevant conclusions and
advance our understanding of progression toward a cancerous cell state.
1.3.4 Therapeutic potential
The earliest cancer therapeutics were targeted at the main deregulated phe-
notypic aspects of cancer cells, but are also highly toxic for the patient. For
instance, the Achilles heel of cancerous cells proliferating in an uncontrolled
manner is at the moment of their replication. Since these cells replicate
at a higher frequency than healthy cells, targeting drugs at the replication
machinery has been a strategy to hit malignant cells. Healthy cells still repli-
cate albeit at a lower rate, and thus chemotherapies based on this mechanism
show high toxicity and carry many adverse eﬀects for patients.
The advent of high-throughput sequencing brought about the concept of
personalized medicine, where patients are administered a drug regimen tai-
lored to their personal mutational profile. In the case of BCR-ABL in blood-
related cancers, a physician might prescribe a diﬀerent duration of imatinib
treatment before switching to an alternative kinase inhibitor depending on
the exact genetic fusion breakpoint. This shift toward the development of
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personalized therapeutics has been heralded as the next breakthrough in
cancer therapy, however its success has been limited. Indeed, cancer cells
tend to develop resistance to drugs by e.g. mutation of a kinase’s active
site resulting in decreased inhibitor aﬃnity. Network medicine was first de-
scribed as a systems approach to understanding disease taking advantage
of network properties [82]. Going one step further, it has been speculated
that a multi-pronged therapeutic approach where several network nodes are
targeted either simultaneously or in succession could, if adequately dosed,
address the limitations of current personalized medicine attempts [83].
As discussed in more detail in Chapter 2, an eﬃcient gene editing tool
such as CRISPR-Cas9 could provide potentially enormous therapeutic ad-
vances. Still, this technology has several limitations in common with siRNA-
mediated gene silencing (RNAi), such as diﬃculty in delivery and oﬀ-target
eﬀects. Additionally, the permanent nature of these genetic modifications
render these issues perhaps even more critical than in the case of RNAi.
Imagining a context where all these limitations were insignificant, this tech-
nology would render genetic diseases amenable to permanent cure. This
would be the only way to directly target the many chromosomal aberra-
tions, such as SNPs or rearrangements that are currently being identified in
high-throughput patient tumor profiling initiatives.
1.4 Fusion proteins and signaling networks
Transformation in the presence of kinase fusion genes is in reality the con-
sequence of the de-regulation of signalling pathways that control cell pro-
liferation and inhibition of apoptosis. TK fusions, via their kinase moiety,
are thought to directly or indirectly elicit events leading to transformation
such as genomic instability, deregulated cell growth, as well as subversion of
the apoptosis program for cells with DNA-damage [84]. As a result of the
history of discoveries involving chromosomal translocations, a large portion
of the work focuses on the understanding of BCR-ABL, as well as on a few
alternative fusions found to direct cells toward a leukemic state. Two recent
proteomic studies focused on the signaling diﬀerences between isoforms of the
BCR-ABL fusion [85], [86]. The two studies found changes in the signaling
network, despite the kinase domain being preserved in both isoforms.
Despite the confounding literature and the lack of large-scale studies,
some commonalities emerge among tyrosine kinase fusions implicated in
leukemia [nicely reviewed in [44]]. The preservation of the oligomerization
domain allows autophosphorylation of the protein, through which down-
stream signal eﬀectors are activated which in turn lead to transformation
in hematopoietic cells. A necessary condition for transformation is the sub-
version of normal constraints on cell cycle control, allowing for unrestricted
entry into mitosis. Studies show that induction of mitogenic pathways due
to the fusion protein are central to transformation. Replicative stress then
creates a state of genomic instability where accumulation of mutations and
further DNA-damage can occur. In turn, this then provides the context for
a modification in the equilibrium between pro- and contra-oncogenic states.
Finally, survival signals are triggered by the fusion kinase to avoid entry into
apoptosis. Some pathways therefore appear to be commonly de-regulated:
the phosphatidylinositol-3-kinase (PI3K) pathway, mitogen-activated protein
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kinase (MAPK) pathways, STAT-family proteins, and NF-B. Some exam-
ples of the conflicting studies regarding the process of fusion kinase-mediated
transformation follow.
1.4.1 Proteomic studies of chromosomal translocations
The majority of studies to date consider the fusion protein and its eﬀects
downstream of a pathway of interest. Recently, there has been an increase
in experiments using large-scale proteomics and phospho-proteomics to gain
a more quantitative understanding of the eﬀect of translocations although
the bulk pertain to BCR-ABL1 and the eﬀect of associated tyrosine kinase
inhibitors [87]–[92]. The use of mass spectrometry in addition to other high-
throughput data sources provided the ability to accurately quantify the ef-
fects of kinase inhibitors or combinations thereof on the state of cells, thus
suggesting a mechanism for drug interactions and activity. Fairly few are har-
nessing the power of this fast-developing technology to obtain a global view
of the signaling occurring due to the expression of the many less well-known
fusion kinases, the path to cellular transformation, and the maintenance and
progression of cancerous cells [93]–[96]. As discussed in a review by Turner
[44], there are likely commonalities among these proteins that remain to be
discovered.
While cases of patients harboring novel chromosomal translocations are
constantly discovered, it will be critical to delve into a deeper understanding
of the mechanisms governing their creation, development, and eﬀects in order
to translate this wealth of data into therapeutic strategies.
Two recent studies aimed at understanding the diﬀerence in expression
of the BCR-ABL p210 and p190 isoforms with respect mainly to signaling,
relevant due to the diﬀerence in clinical outcomes [85], [86]. While a number
of studies had used mass spectrometry to study the BCR-ABL rearrangement
these were the first to perform a quantitative systematic analysis in the same
cellular background. The studies both concluded that although the isoforms
have similar kinase activation, there are a number of diﬀerentially regulated
interactors and downstream signaling partners, namely members of the Stat
as well as the Src families.
In order to study the eﬀects of proteins on the cell, the cellular context as
well as the method of introducing the perturbation is key to maintaining bio-
logical relevance of the study. Rather than overexpressing fusion constructs,
the low frequency of translocations is preserved when using a nuclease to gen-
erate specific double strand breaks [97]. This has been done with engineered
Zinc-finger nucleases as well as TALENs [98] [99], and more recently using the
CRISPR-Cas9 system [100]–[102]. Choi et al. created several rearrangements
(CD74-ROS1, EML4-ALK, KIF5B-RET) as did Torres et al. (EWSR1-FLI1
and RUNX1-ETO). The fusions were induced in various cell lines at a low fre-
quency (<10% of targeted cells carried the rearrangement), and were shown
to be at precisely the desired intronic location, demonstrating the success
of using nucleases to generate double strand breaks and subsequent isola-
tion of the desired translocations. Moreover, Maddalo et al. demonstrated
that this strategy is also applicable in vivo. The low frequency of rearrange-
ment is certainly a limitation to the experimental study of fusions using this
method, but also likely reflects the physiological conditions in which fusions
occur. Moreover, the increase in papers using CRISPR-Cas9 in genome-wide
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screens [103] confirms the use of this method for large-scale studies such as
mass spectrometry-based proteomics. It should be noted however that oﬀ-
target eﬀects of nucleases are recognized but not yet fully understood and
are a limitation of the use of nucleases that should be taken into account
(discussed in Chapter 2).
1.4.2 Mass spectrometry-based proteomics
Where next generation sequencing identifies abnormalities in the genomes
of cancerous systems, high-throughput proteomics allows a quantitative as-
sessment of their consequences one step closer to the phenotypic level. The
cancer community still lacks a robust understanding of how genomic events
impact the proteome and phosphoproteome of a cell, resulting in phenotypic
changes that are then identified as disease. Measurement directly at the
proteomic level is essential for a complete understanding of the biological
systems at hand as data generated by genomics or gene expression studies
does not provide an accurate representation of protein abundance nor of their
dynamics.
For the large-scale analysis of proteins in ’discovery mode’, liquid chromatography-
tandem mass spectrometry has emerged as the preferred technology. The
typical "bottom-up" proteomics workflow involves the tryptic digestion of
proteins into peptides, which are then separated by reverse phase liquid chro-
matography. Voltage applied to the eluate ionizes peptides, and these ions
are transferred to the gas phase for direct injection into the mass spectrom-
eter. A detailed description of the electronics residing inside modern mass
spectrometers and the physico-chemical reactions occurring within are com-
plex and beyond the scope of this introduction. Briefly, the mass-to-charge
(m/z) ratio of the ionized peptides (precursor ions) is measured in a mass ana-
lyzer (common mass analyzers include the Orbitrap, ion trap or time-of-flight
(TOF)). In the case of the Orbitrap, ions are trapped around an electrode,
and the frequency of rotation and oscillation of the ions around the electrode
are recorded over time. Using a Fourier transform, these measurements are
then converted from a time into a frequency domain from which the mass-
over-charge ratio of an ion can be inferred. Once the m/z precursor peptides
are measured (MS), a subset of ions are chosen based on abundance and
charge and selected for further fragmentation (fragment ions). To fragment
ions, ions of desired mass are isolated and excited into colliding with gas ions
(e.g. helium) causing fragmentation of the precursor ion’s chemical bonds.
These fragmented ions are then sent to a mass analyzer, where their m/z
and intensity are acquired (MSMS). The data acquired for these precursor
ion-fragment ion pairs is then searched against a database of spectra in order
to identify the amino acid sequence of the tryptic peptide. Quantification
can be achieved e.g. by comparing the abundance of ions (label-free quantifi-
cation) or by using isotopic labeling, whereby stable amino acid isotopes are
incorporated into the proteins of a sample to compare with, and then mixed
at a known ratio.
The advent of “shotgun” mass spectrometry-based proteomics has pro-
vided researchers with the capacity to measure thousands of proteins within
a single sample, a drastic increase from the well-established antibody-based
proteomic techniques such as reversed phase protein arrays where antibody
availability limits the scope of an experiment. Additionally, antibody-based
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quantitation methods are typically based on a single epitope, yielding only
a semi-quantitative picture of protein levels. Therefore, a focus of develop-
ing mass spectrometry-based methods has been precise and accurate protein
quantitation, some well-established approaches being isotope labeling with
amino acids in cell culture (SILAC), isobaric labeling (iTRAQ, TMT) and
label-free quantification (LFQ) [104]–[107].
Signaling via post-translational modifications (PTM) such as phosphory-
lation, glycosylation and ubiquitination, as well as their cross-talk, are criti-
cal in modulating the cell’s response to external and internal stimuli. Impor-
tantly, analysis of phosphorylation is critical in understanding the rewiring of
protein networks upon genetic alterations. PTM enrichment strategies allow
the measurement of various sub-proteomes such as the phospho-proteome or
glycoproteome providing an additional dimension to global proteomics. Gen-
erating quantitative data for PTM sub-proteomes is an important addition
to the omics list, since this post-translational information can by definition
not be gleaned from the genetic or transcriptomic levels. More importantly,
changes in levels of post-translational modifications reflect properties of a
protein, such as a change in protein activity or conformation.
Phosphorylation in particular is a well-studied PTM and the phosphory-
lation state of proteins in a cell or system is measured via mass spectrometry
of the phosphorylation-enriched proteome, informing on the activity, local-
ization and stability of the phosphorylated protein. This is typically done
before and after a biological perturbation (drug, stimulation, etc.) in or-
der to understand the changes occurring in the cellular network of modified
and unmodified proteins. This can to some extent also inform on the up-
stream kinase activity, although it should be underlined that this method
provides a measure of kinase activity via a proxy and is therefore an in-
direct measurement. Other processes such as additional PTM regulation
(e.g. ubiquitination, glycosylation), may lead to uncorrelated kinase and
phosphorylation-site measurements, complicating the analyses. The combi-
nation of multiple types of mass spectrometry data can fill the voids left
by individual experimental setups: for example, measurement of the en-
tire proteome, the phospho-enriched proteome, and immuno-enrichment of
phospho-tyrosine residues have been combined [108], [109].
Proteomics has demonstrated its power in identifying and quantifying
proteins and biomarkers in cells as well as in diﬀerent tissue types. With
the advent of ever more sensitive and fast instruments the focus has shifted
toward a more systems approach profiling proteins across many perturbation
states and time points. While this has certainly furthered our understanding
of the roles of proteins involved in e.g. disease vs. healthy states, there
is much room for improvement. For instance, the quantification methods
touched upon above are for the most providing relative protein quantification.
Robust absolute quantification will likely be an important advance for the
proteomics community in the future.
1.5 Proteomic data integration strategies
Due to the biases each technology and experimental design is associated with,
the collection and analysis of complementary datasets is one approach in an
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eﬀort to move toward a more complete representation of the studied sys-
tem of interest. With this in mind, the Clinical Proteomic Tumor Analysis
Consortium (CPTAC) [24] was created in order to add an additional omics
dimension to the large-scale genomic cancer datasets, and thereby build on
previous eﬀorts. The CPTAC uses multiple stages of mass spectrometry-
based proteomics: a discovery phase where global proteomic profiling is per-
formed on a select subset of tumors that have been genetically characterized
by TCGA to identify proteins of interest, and a second validation phase dur-
ing which targeted assays are performed in order to monitor the proteins of
interest, e.g. potential biomarkers or drug targets. The first phase integrates
genomic prior data into proteomic analysis by providing an improved anno-
tation of the reference genome/proteome, and by providing a list of genetic
mutants on which to confirm peptide-level mutants.
1.5.1 Data heterogeneity
Integrating data from multiple sources presents a major diﬃculty due to the
inherent diﬀerences of the individual technologies. In some cases data might
be available for a population of cells (e.g. RNA-seq, mass spectrometry),
whereas others provide an output at a single-cell level (e.g. imaging, single-
cell mass cytometry). Another diﬀerence is sensitivity; discovery proteomics
focuses more on the broadest identification of the system’s components, in
order to lay a network map of proteins in the system. Therefore, a lacking
protein identification does not necessarily signify that the entity is truly
lacking. Rather, its abundance was not suﬃcient in order to be confidently
identified. Targeted mass spectrometry techniques on the other hand are
capable of high sensitivity and may be used to determine the presence or
absence of a peptide in a given sample.
Using multiple techniques side-by-side separately to provide orthogonal
evidence supporting a particular finding is nowadays expected to support
major findings, however integrating large datasets in a systematic manner
is far from straightforward. Additionally, due to the features of the various
data types, diﬀerent modeling approaches are required.
1.5.2 Proteogenomics
One example of successful integration is that of sequencing and proteomics
at a qualitative level, or proteogenomics [110], [111]. In this case, exome se-
quencing or RNA-seq data is used to create a sample-specific list of gene and
therefore protein sequences, which can then be used to query proteomic data
by feeding this novel information into a reference database. This is especially
well-suited for patient tissue analysis where a time-course setup is diﬃcult to
implement and it is therefore diﬃcult to study the evolution of the disease.
In order to gain as much insight as possible when analyzing patient samples,
proteomic and genomic measurements may be acquired from the same tis-
sue sample and the patient’s genetic profile can be used for a more informed
proteomic analysis. This data can then be overlaid on known protein-protein
interactions to infer regulatory networks. Indeed, a genetic alteration (such
as SNPs, frameshifts and splice isoforms) leading to an alternative protein
isoform would be missed in a proteomic experiment without inclusion of this
variant in the search database. Mertins et al. have found that detection
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of genomic variants in mass spectrometric data is sparse, partly due to the
incomplete coverage of proteins by the individually measured peptides [110].
Rather than use mass spectrometry to confirm genetic alterations directly
as alternative protein isoforms, genetic variants may be identified and subse-
quent changes in protein expression or PTM regulation can be determined.
It is in this context of increased knowledge of the chemical space of protein
isoforms that we apply this technique in the projects described in part II.
1.6 Context of this thesis
The studies in part II are examples of creating a cellular perturbation akin to
those occurring in a disease setting and subsequently sampling this altered
network. Chapter two is an introduction to chapter three in which the eﬀect
of a genetic perturbation, the generation of a chromosomal translocation, is
assessed at the protein abundance, signaling and phenotypic levels. Chap-
ter four perturbs a cell population directly at the level of signaling using a
2D wound assay and identifies signaling changes associated with increased
migration. Although diﬀerent in many aspects, the two studies share the un-
derlying assumption that a perturbation is not an isolated event leading to
a single outcome. Rather, the eﬀects reverberate throughout the network of
interacting proteins, the consequences of which may be the evolution towards
an increasingly malignant state.
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Chapter 2
Harnessing gene-editing
techniques for the generation of
chromosomal aberrations
This chapter provides a historical overview of the gene editing technologies
and how they furthered research in the life sciences, including the latest
addition to the genetic engineering arsenal: CRISPR-Cas9. It is concluded
by an introduction to chromosomal rearrangements and their genesis using
nuclease-based gene editing.
2.1 Precision Genome Editing for Systems Biology
- A Temporal Perspective
Originally published as : Voellmy, F. and Linding, R. (2017) Precision
Genome Editing for Systems Biology - A Temporal Perspective, in Systems
Biology (eds J. Nielsen and S. Hohmann), Wiley-VCH Verlag GmbH & Co.
KGaA, Weinheim, Germany.
Over the past 60 years, the development of techniques allowing the pro-
duction and manipulation of DNA has provided molecular biologists with the
tools to make many of the major advances impacting basic science, biotech-
nology, and medicine. The discovery that endogenous nucleases could be
exploited for their sequence-specific DNA-cleaving abilities within the cell or
organism itself allowed biologists to probe the eﬀects of gene modification,
which is essential to the understanding of gene function. In this chapter we
will cover the emergence and development of the gene-editing era over time
beginning with zinc-finger nucleases (ZFNs) and transcription activator-like
eﬀector nucleases (TALENs), and continue with the newest popular tech-
nique of clustered regularly interspaced short palindromic repeat (CRISPR),
which, since its demonstration to be applicable as a DNA editing platform
in 2013, has already been adopted by many research groups worldwide. The
ease of design of this technique has rendered it amenable to high-throughput
studies, such as genome-wide loss-of-function screens in mammalian cells and,
as a consequence, also to systems biology. As the technique establishes itself
and becomes potent for clinical applications such as gene therapy, nuclease
specificity and oﬀ-target identification must be thoroughly examined. We
will therefore also cover important considerations for the design of nuclease-
based gene-editing research projects. Finally, we will focus on the study of
chromosomal rearrangements that can be induced by means of two DNA
double-strand breaks (DSB)s using sequence-specific nucleases, and thereby
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present an interesting application of the CRISPR-Cas method for systems
biology.
2.2 Early Techniques in DNA Alterations
The advent of recombinant DNA technology in the 1970s was at the origin
of the gene modification trend using enzymes purified from bacteria to cut
and ligate DNA, and further using the bacteria as a host to produce the
DNA of interest in large quantities, allowing the targeted alteration of DNA
molecules. A gene cloned using this technology could then be introduced into
living cells via homologous recombination [1]. Several studies have reported
the possibility of transferring a modified, cloned sequence to the germline of
a living organism by genetically manipulating murine embryonic stem cells
established in culture. When reintroduced into mouse blastocysts, these cells
were capable of colonizing germ cell lineages, and the introduced genes, for
example conferring antibiotic resistance [2] or essential to cellular building
block production [3], were transmitted into the transgenic generation. These
studies underlined the vast potential of gene therapy, notably to correct genes
carrying a malignant mutation. Moreover, the advantage of performing site-
specific genetic manipulation without having to extract the DNA from its
genomic context was apparent. Work carried out in bacteria and yeast to
understand natural DNA repair pathways showed that cells possess the ma-
chinery to repair dangerous DSBs in their DNA [4], and suggested that de-
termining methods to create precise breaks, along with recombinant DNA
technology, would be critical for genome editing. Early techniques to create
DSBs already made use of DNA base pair recognition by oligonucleotides or
small molecules. Molecules capable of recognizing DNA sequences were cou-
pled to cleavage reagents such as bleomycin, thereby creating a system for
site-targeted modification. Although not applicable on larger scales, these
studies underscored the idea of using base-pairing to a host’s DNA as a
means for site-specific binding [5]–[8]. One example of an early technique us-
ing nucleases, which is based on base-pair recognition, is self-splicing introns
capable of modifying DNA or RNA sequences. Yeast mobile group II introns
such as aI1 and aI2 encode reverse transcriptases that convert intron RNAs
into complementary DNA (cDNA) and insert the intron at a high frequency
at the same site in an intronless allele [9], [10], also known as “homing.” To do
so, an intron-encoded endonuclease acts as a ribozyme, with the excised RNA
creating a break in the sense strand and the protein moiety in the antisense
strand of the double-stranded DNA at a precise location, allowing the inser-
tion of the intron into the genomic DNA [11]. Interestingly, although the aI1
and aI2 self-splicing introns are closely related, their respective insertion sites
are diﬀerent, suggesting endonuclease specificity [12]. Similarly, based on a
self- splicing intron discovered to mediate trans-splicing of oligonucleotides,
a targeted RNA-cleaving ribozyme was demonstrated to be suitable for al-
tering the sequence of specific transcripts [13]. By fusing the domains of two
existing endonucleases, a highly sequence-specific artificial endonuclease was
created [14]. Although the methods introduced up to this point make use
of Watson–Crick base pairing in to recognize specific genetic sequences, they
lack flexibility and scalability. The following technologies, namely zinc-finger
nucleases, transcription activator-like eﬀector (TALE) nucleases, and most
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recently CRISPR-Cas systems, build on the use of base pairing but are suf-
ficiently modulable to – in theory – recognize any DNA sequence occurring
in complex genomes.
2.3 Zinc-Finger Nucleases
The zinc finger is a     ↵ domain with a zinc ion coordinated by two cys-
teine and two histidine residues, recognizing three consecutive base pairs [15].
Zinc-finger domains [16], [17] can be tethered to the sequence-independent
DNA cleaving domain of the bacterial restriction endonuclease Fok1 [18],
thereby creating a site-specific nuclease where the target sequence recogni-
tion is dictated by the DNA-binding domain (DBD) of the zinc-finger protein.
Zinc-finger domains are often found as tandem repeats, permitting the recog-
nition of asymmetric sequences. Structural advances in the field have enabled
the generation of synthetic arrays of over three zinc-finger domains by modi-
fying the linker between repeats, allowing virtually any 18-bp sequence to be
targeted [19], a length suﬃcient to be unique even in a genome as complex
as Homo sapiens’ [15]. The approach was successfully demonstrated to intro-
duce mutations in Drosophila as well as mammalian cells [20], [21], and it can
be used to introduce diﬀerent genomic alterations such as point mutations,
deletions, insertions, inversion, duplications, and translocations [22]. It nev-
ertheless remains diﬃcult to adapt to large-scale applications where many
sequences are targeted, because of tedious protein design requiring many
steps (indeed, clever design alone is not suﬃcient, and selection strategies
must be applied to optimize the zinc finger for a target) [19].
2.4 TALENs
A similar approach was applied to generate an improved version of natu-
rally occurring bacterial TALEs, by fusing the TALE DBD to various other
functional domains. TALEs are naturally encoded by the plant pathogenic
bacteria Xanthomonas spp., and when injected into host cells have the ca-
pacity to alter transcription by binding to genomic DNA, thereby increasing
pathogenicity. These proteins are comprised of a series of 33–35 amino acid
repeats, each recognizing 1bp. For genome editing purposes, arrays of highly
conserved repeats derived from the DBD of TALEs can be customized to
recognize specific DNA motifs. Within each repeat of an array, two amino
acid residues named repeat variable diresidues (RVD)s [23] are responsible
for specificity in binding of a single nucleotide [24], and the assembly of re-
peats with selected RVDs determines the target sequence and its length. The
unraveling of this RVD-to- protein code [24], [25] enabled researchers to engi-
neer the DBD to target any sequence of interest (typically 15–20bp [26]–[28])
and thereby customize this system with more ease than previous methods.
However, this means that a new DBD needs to be engineered for each 15 – 20
bp target, requiring significant time and eﬀort. Indeed, extensive identical
repeats can present synthesis challenges, and methods have been developed
to work around this limitation [28], [29]. TALE DBDs can be combined
with a Krüppel-associated box (KRAB) domain to achieve gene silencing by
targeting the KRAB to transcription start sites. Transcription is thereby
repressed in the nucleus, rather than being degraded post-transcriptionally
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as is the case with RNAi. In order to induce DSBs, TALENs are created
by fusing the Fok1 nuclease eﬀector domain to the DBD of TAL (transcrip-
tion activator-like) [30]. Since Fok1 requires dimerization for activity, this
imposes a requirement to have a pair of TALEN for the correct positioning
of Fok1 domains with respect to the desired cut site. This, in turn, strongly
increases specificity of directed DSB [31], and oﬀ-target eﬀects are typically
low [27], [32], [33].
Despite the aforementioned diﬃculties in TALE design, a study by Kim
et al. [34] targeted over 18 000 genes by constructing a TALEN library,
thereby demonstrating the potential of these nucleases to large-scale studies.
2.5 CRISPR-Cas9
The most recent addition to the programmable nuclease toolbox is the CRISPR-
Cas system. In 2007 [35], it was shown that the CRISPR-Cas system was
able to confer adaptive immunity [36]–[38] to Streptococcus thermophilus bac-
teria against phage infection. From an industrial viewpoint, the ability to
aid the workhorse bacterial starter cultures in overcoming phage exposure
remains an area of application that is of great financial interest [39]. Briefly,
this system, which is widespread in bacteria and archaea, allows the incor-
poration of short fragments of DNA from invading viruses or plasmids into
the organism’s own genome, and upon future encounters with the same virus
or plasmid family, the latter threat can be decimated by targeting DNA
matching the previously incorporated sequences [40] (Fig. 2.1). This an-
tiviral defense is the result of a series of events. First, a short fragment
of the foreign DNA is incorporated into the CRISPR array, which is an
array of identical repeats interspersed with invader DNA-targeting spacers
of approximately 20 bp, called protospacers. These spacers are transcribed
as precursor CRISPR RNA (pre-crRNA) and are then further processed to
become individual CRISPR RNAs (crRNAs), serving as guides for Cas pro-
teins to interfere with invading DNA. The CRISPR-Cas loci also transcribe
an operon of cas genes. The encoded Cas protein components then cleave the
invading DNA at locations complementary to the crRNA sequence. Several
CRISPR-Cas systems have been found to follow this overall scheme, with
diﬀerences in the exact mechanisms governing site recognition and cleavage,
and have been classified into three main types I, II, and III, along with sub-
types for each [41], [42]. The system types diﬀer in the expressed Cas proteins
and their mode of action. The type II system has proven to be most useful
for genome editing purposes because of the fact that it requires only a single
Cas protein, Cas9 (previously known as Cas5, Csn1, or Csx12), to mediate
both sequence specificity and nuclease activity [43]–[45].
In contrast, type I and III systems rely on a large multimeric crRNA
– Cas ribonucleoprotein complex, which results in a setup of greater com-
plexity is and thus less amenable to development as a gene-editing tool.
Trans-activating crRNA (tracrRNA) is a small noncoding RNA that is com-
plementary to the repeated sequences in the pre-crRNA, and is utilized by
the type II CRISPR-Cas system in Streptococccus pyogenes for pre-crRNA
processing by binding to the crRNA and triggering cleavage by RNase III
(in presence of Cas proteins), and has also been reported to be necessary for
nuclease sequence specificity. Jinek et al. then demonstrated that the final
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Figure 2.1: Schematic of the type II CRISPR- Cas9 mech-
anism of adaptive immunity. Invading DNA is incorporated
into a CRISPR array, alternating between repeated short
fragments of foreign DNA of approximately 20bp (proto-
spacer) and identical repeats (PAM). The CRISPR locus
is transcribed into pre-crRNA and finally, after binding of
tracrRNA to pre-crRNA, matures into crRNA. crRNA and
tracrRNA form a duplex triggering cleavage of target DNA
by the Cas9 nuclease.
CRISPR-Cas9 complex was a dual-RNA-guided DNA endonuclease in which
a tracrRNA:crRNA duplex is formed and bound to Cas9, directing it to a
target with complementarity to the crRNA [43].
2.6 CRISPR-Cas9
The protospacer adjacent motif (PAM) is an essential component of the type
II system and is found flanking the 3’ end of the target site, for example, 5’
NGG for S. thermophilus and S. pyogenes. The critical nature of the PAM
was shown by PAM mutations in phage genomes interfering with the antivi-
ral defense mechanism [46]. The RNA–DNA duplex is formed first at the
PAM site and then allows interrogation for upstream complementarity. In
support of this, catalytically inactive Cas9 mutants were found to bind at
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many more sites than the expected exact sequence matches. These sites were
typically adjacent to a PAM and presented partial complementarity to the
guide sequence. However, active Cas9 infrequently cleaves at these oﬀ-target
sites, thereby pointing toward uncoupled DNA recognition and cleaving [47].
The family of Cas9 proteins possesses two signature nuclease domains: HNH
and RuvC. When there is complementarity between the crRNA and the
guide sequence, the Cas9 HNH domain cleaves the complement to the 20-nt
sequence of the crRNA, whereas the RuvC domain cleaves the noncomple-
mentary strand. Nickases that create a single break rather than a DSB can
be engineered by mutating one of the two domains depending on the strand
where cleavage is desired [43], [44]. Elucidation of the crystal structure of S.
pyogenes [48], [49] showed that, when dissociated from guiding elements, the
Cas9 protein remains in an auto-inhibited conformation in which the HNH
domain active site is blocked by the RuvC domain. Further simplifying the
practical application of the CRISPR-Cas9, the tracr- RNA:crRNA complex
was found to be replaceable by a single guide RNA (sgRNA) of 20 bp [43].
This short RNA is essentially a combination of the tracrRNA and crRNA,
where the guiding properties of the crRNA and the secondary structure of
the duplex required for DNA cleavage are maintained. This allowed a system
where the simple change of the sgRNA could re-target Cas9 to any sequence
adjacent to a PAM. The implementation of the CRISPR-Cas9 as a gene
editing tool was shown in several studies [50]–[53], as well as the possibility
of “multiplexing” where multiple sgRNAs are used for targeting [50], [51].
Moreover, similar to fusion TALE DBDs with KRAB domains, mutant Cas9
can be fused to eﬀector domains such as KRAB to induce transcriptional
repression.
2.7 Considerations of Gene-Editing Nuclease Tech-
nologies
2.7.1 Repairing Nuclease-Induced DNA Damage
After the DNA DSB created by one of these methods, diﬀerent repair path-
ways may be stimulated in mammalian cells: the error-prone non-homologous
end-joining (NHEJ), or the high-fidelity homology-directed repair (HDR)
[54]. These repair mechanisms can be taken advantage of to introduce tar-
geted alterations in the DNA sequence [22]. The HDR pathway is critical
in maintaining genetic stability and preventing cancer-related genetic alter-
ations, and can be activated upon DSB if a donor template is provided via
an unbroken sister chromatid or homologous chromosome, or supplied by an
external source. The HDR pathway, which is less error-prone than NHEJ,
when presented with a template double-stranded DNA sequence partially
overlapping with the region surrounding the DSB, can lead to the precise in-
troduction of mutations or entire sequences up to 7.6 kb [55]. Alternatively,
NHEJ mediates inaccurate repair of the DSB, often resulting in substitutions
at the target site as well as insertions or deletions (indels) [20], [56], [57]. In
the case where the DSB site is within a coding region of a gene, the NHEJ
repair machinery promotes frameshift mutations, potentially resulting in the
knock-out of gene function [58]–[60]. Indels introduced by NHEJ after a DSB
can vary from a few nucleotides to tens of nucleotides [61]. Large deletions
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(several megabases) [62] as well as inversions [63] can be induced by cut-
ting at two distinct sites on the same chromosome, whereas translocations
[64]–[68] can be created with DSBs on diﬀerent chromosomes. The type of
DNA break can be used to influence whether HDR or NHEJ will mediate
the repair. Indeed, nicks (i.e., single-strand breaks rather than DSBs) can
stimulate the involvement of HDR [50], [51], [69]–[71]. Specific insertions
are mediated by supplying cells with a double-stranded template, making
use of the HDR pathway. Despite this, activation of NHEJ can still lead to
undesired alteration of the targeted genomic site. Development of methods
that favor HDR over NHEJ will be important to reduce unwanted adverse
eﬀects, and also for systems employing the Cas9 nuclease for site-specific
introduction of new genetic material.
2.7.2 Nuclease Specificity
In order for programmable nucleases to be amenable to use in a clinical set-
ting, as well as to be truly relevant to biological research in the context of
complex genomes, their exact mechanism of action needs to be determined
in order to confidently predict and assess potential oﬀ-target cleavage activ-
ity. Recognizing that all nucleases carry imperfections to some degree and
addressing the question of target specificity are especially critical, given the
permanent nature of these modifications. This should be a concern both
when choosing guide sequences for a desired target and during the investi-
gation of oﬀ-targets as a “by-product” of nuclease activity. The first point
can be addressed using several online tools that have been developed to aid
researchers in their choice of target sites for a particular CRISPR-Cas appli-
cation aiming to achieve a high “on” rate; they have recently been reviewed
and compared [72], [73]. Some examples include sgRNA Designer and sgRNA
Scorer [74], [75], which Lee et al. [73] have shown to have poor overlapping
top ranking hits. Cross-checking the sites given by diﬀerent prediction algo-
rithms could be one way of selecting top targets. Experimental validation of
nuclease on-target activity can be carried out in several ways. Most methods
detect indels generated by DSB repair by the NHEJ pathway, either using
enzymes and separating the cleavage products on an agarose gel [76], or by
Sanger sequencing of clones [61], [77] or the entire population [78]. Hen-
del et al. [61] developed a method called single-molecule real-time (SMRT)
sequencing, which is capable of detecting both HDR and NHEJ repair fol-
lowing DNA DSB. An alternative is the BLESS (direct in situ breaks label-
ing, enrichment on streptavidin, and next-generation sequencing) technique,
which labels DSBs and, following enrichment, makes use of next-generation
sequencing to directly measure DSB levels [79]. Assessment of the extent
of oﬀ-targets of a gene-editing nuclease system can be performed by iden-
tifying expected at-risk sites and monitoring these for undesired cleavage
events. This is rendered diﬃcult because of large genome size and the large
number of potential cleavage sites, in addition to cleavage of identical sites
depending on genomic context [80]. Thorough determination of the extent
of nuclease promiscuity could be achieved by less biased methods, for ex-
ample, whole-genome sequencing [81]. In the case of ZFNs and TALENs,
structure- and selection-based approaches [82], [83] have been developed to
improve specificity and reduce toxicity, and several assays have been devel-
oped to determine their specificity [81], [84]. These are typically applied
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to individual nuclease systems, as a systematic evaluation remains elusive
because of the diﬃculty in generating proteins with varying sequence speci-
ficity. In the case of the CRISPR-Cas9 system, target recognition is imposed
by base-pairing interactions between the guide RNA with its target sequence
as well as recognition of the adjacent PAM sequence, and is therefore poten-
tially well suited to probe the eﬀects of mismatching at genome-wide levels
[52], [72], [85], [86]. These studies have shown that the extent of oﬀ-site
targeting, defined as the tolerance of Cas9 to mismatches in the RNA guide
sequence, is dependent on the number, position, and distribution of mis-
matches spanning the guide sequence as opposed to previous suggestions of
a 8–12 nucleotide specificity-determining seed region [43], [50]. Deviations
in the PAM sequences are less well tolerated in comparison to mismatches
within the target sequence, although Cas9 recognizes alternative PAMs to
the optimal NGG: NAG, NGA, NCG, NGC, NGT, NTG, and NAA [72], [87].
Selecting a Cas9 ortholog derived from a diﬀerent species may provide higher
binding specificities [88]. Oﬀ-target sites can be organized into three groups
depending on their diﬀerences with the true target sequence: sequences of
same length but containing base mismatches; shorter sequences with miss-
ing bases; and longer sequences containing more bases [89]. More recent
studies have shown that CRISPR-Cas systems display significant nonspecific
nuclease activity at oﬀ-target sites containing several mismatches with the
desired target [52], [72], [85], [86], [90], thus underscoring the importance of
developing methods to globally assess oﬀ-target activity.The consequences of
these mismatches may vary depending on the application of interest using
Cas9, given its decoupled target recognition and cleavage activities. Indeed,
although Cas9 may be tolerant to a number of mismatches
2.8 Considerations of Gene-Editing Nuclease Tech-
nologies
throughout the length of the guide sequence in terms of recognition, its cleav-
age activity is more conservative [91]. Ran et al. have shown that by em-
ploying an approach based on pairs of oﬀset guide RNAs and a mutant Cas9
nickase, specificity can be increased by up to 1500 times that of wild-type
Cas9 [92], [93]. This is achieved by the two nicks at the target site eﬀectively
resembling a DSB, thereby promoting indel formation, whereas any oﬀ-target
eﬀects from the nickase are precisely repaired. It should be noted that this
increase in specificity might in large part be due to the fact that a pair of
Cas9 nickases recognizes double the length of a single sgRNA, that is, 40 nt
rather than 20 nt, which one would expect to have a significant impact on
selectivity. Moreover, Cas9 nickases are not under the requirement to dimer-
ize (as is the case for zinc-finger nuclease systems), and oﬀ-targets may still
be generated for the individual sgRNA [87]. Introducing sgRNAs truncated
by two or three nucleotides can increase on-target activity, and it is hypoth-
esized to do so by increasing sensitivity to mismatches [94]. Another way to
circumvent oﬀ-target eﬀects as well as the mentioned shortcomings of Cas9
nickases is by fusing a mutant Cas9 to Fok1, where two of these monomers
bind diﬀerent target sites simultaneously [32], [87].A number of online tools
exist for the prediction of oﬀ-targets, although the accuracy with which alter-
native cleavage sites are inferred is unclear [73]. Tsai et al. [87] compared the
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ranking of oﬀ-target predictions generated by two tools, CRISPR Design [92]
and E-CRISP [95], both based on the number and position of mismatches,
with experimentally determined oﬀ-target sites. Both tools were found to
have missed many of the true positive oﬀ-target sites. An improved tool,
COSMID [80], takes into account partially matched sequences containing
base mismatches, as is currently the case, as well as base insertions and dele-
tions. Other resources such as Cas-OFFinder provide similar options [96].
A better understanding of target site accessibility is expected to improve
the available prediction algorithms. In order to comprehensively survey the
oﬀ-target space, the best strategy would be to pool the results of several of
the above-mentioned resources. The large number of oﬀ-targets that are sug-
gested by this more extensive analysis will require experimental confirmation.
Methods to investigate this are required to be as unbiased as possible, as well
as high throughput, in order to cover the entire genome and all the expected
oﬀ-target sequences in a time- and cost-eﬀective manner. Recently devel-
oped methods focus on the detection of DSBs to determine sites aﬀected by
nuclease activity. A Cas9 mutant possessing intact recognition but without
the capacity to cleave was used to profile sites of DNA binding by ChIP-seq
[91], [97]. However, this strategy was shown to be problematic because of the
lack of necessary dependence between site recognition and cleavage [87]. The
Digenome-seq method alleviates these issues by digesting intact complexes
of DNA with the bound Cas protein followed by whole-genome sequencing
[98]. The digests that are true oﬀ-sites possess a specific 5’ end that can
be computationally identified, and the method was shown to be comparable
in sensitivity to targeted deep sequencing. A further technique, GUIDE-seq
[87], integrates a short double-stranded oligonucleotide (dsODN) as a tag
at DNA DSBs by NHEJ-mediated capture. These sites are then subjected
to unbiased amplification and next-generation sequencing. Interestingly, in
addition to detecting known and many unknown oﬀ- target sites for sev-
eral diﬀerent sgRNAs, the study also uncovered the existence of genomic
hotspots, where the “dsODN” tag was incorporated independent of a nucle-
ase. Moreover, the search for indels at DSBs led to the identification that
chromosomal rearrangements (translocations, inversions, or large deletions)
could occur at those locations, with or without the help of a nuclease.
2.9 Applications
Gene editing aided by nucleases can be used for a variety of purposes such
as knock-down or site-specific mutagenesis. Zinc-finger nucleases and TAL-
ENs have been used to generate gene knock-downs and introduce mutations.
Their versatility is enhanced when tethered to complementary eﬀector do-
mains, such as, for instance, a fluorescent marker for improved visualization
of protein expression, distribution, and interactions, thus providing alterna-
tives to techniques such as fluorescence in situ hybridization (FISH) [99],
[100]. TALE nucleases can be fused to KRAB or Fok1 domains to mediate
gene silencing akin to RNAi, or to create DSBs, respectively. Furthermore,
when coupled to epigenetic modifying enzymes, the epigenetic landscape of
cells could be probed. Although large-scale studies using TALENs are feasible
[34], for the most part the major advances have been made at a far smaller
scale. It is the ease of design of the latest breakthrough in gene editing,
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namely the CRISPR-Cas system, that holds the promise of rendering nucle-
ases amenable to large-scale systems applications and studies, and on which
we will focus in the next sections. By combining the CRISPR-Cas9 system
with various eﬀector domains, researchers have achieved gene silencing clus-
tered regularly interspaced short palindromic repeat interference (CRISPRi)
[101]), activated gene expression, introduced new sequence elements, or ma-
nipulated Cas9 to act as a RNA-guided homing entity [52]. Experimentally,
the genes needed for the CRISPR-Cas9 platform can be introduced into
cells by means of viral vectors such as lentivirus and adeno-associated virus,
chemical transfection, and others. The use of viral vectors is the preferred
method so far, as they are well characterized and easy to apply. Practical
issues pertaining to the size of the Cas9 gene can be circumvented by shorter
Cas9 orthologs [102], [103]. As discussed previously, the era of nuclease-based
gene editing has spurred a lot of interest in further developing the tools to
reduce their bias and increase specificity. Indeed, this applies to studies us-
ing “omics” technologies to measure global systems responses to perturbation
such as gene knock-out, but also to in vivo applications where the complexity
of the mammalian host renders any interference an inherently systems-level
problem and should be investigated as such (discussed in Section 14.6.4).
2.9.1 CRISPR Nuclease Genome-Wide Loss-of-Function Screens
(CRISPRn)
An application of the CRISPR-Cas technology at a scaled level is to make
use of its nuclease functionality: clustered regularly interspaced short palin-
dromic repeat nuclease (CRISPRn). In this setup, a systematic pooled loss-
of-function genetic screen is carried out by using a genome-wide sgRNA li-
brary to disrupt gene activity for all genes individually [104], [105]. While
RNAi has been widely used for knock-down screens, this setup oﬀers sev-
eral advantages, the major ones being that, since repression occurs at the
DNA level, it is possible (i) to obtain complete loss of function and (ii) to in-
clude non-transcribed elements in the screen such as promoters, enhancers,
and introns. To perform a genome-wide CRISPRn screen, a cell line sta-
bly expressing the Cas9 nuclease is generated. A library of typically 3–5
sgRNAs per gene is created, targeting approximately 20000 genes in total,
and meets criteria to minimize oﬀ-target eﬀects while decreasing the chance
that some genes cannot be probed because of a problematic sgRNA. This
library is then delivered to the Cas9-expressing cells, and individual sgRNAs
are used as markers to ensure a single integration per cell by sequencing.
Moreover, this also acts as a barcode, providing a means to identify cells in
downstream applications. Once knock-down is initiated, cells can be sub-
jected to various conditions such as positive (resistance to drug) or negative
selection [104]–[106], depending on the biological question at hand. To date,
the latter ranges from defining an essential set of human genes to studying
tumor growth and metastasis [107] or the innate immune response [108]. An
additional example of CRISPRn is screens aiming at determining the core set
of essential genes for mammalian cells [109], [110]. By screening the entire
genome within multiple cell types, researchers gain a systematic overview of
genes involved in essential processes; also, they can attempt to determine
patterns emerging from biological systems. In these screens, the CRISPR
technology is used as a means to redefine the genes that are essential to
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all human cells and those that are essential depending on the context, that
is, cell-type-specific. While the core-fitness genes provide a list of essential
genes for further studies, the context-dependent essential genes yield interest-
ing insights into the diﬀerences between human cells [110]. Future research
studying emerging similarities and diﬀerences between cells using orthogonal
methods, such as transcriptomics and proteomics, will yield an additional
layer of insight as to how core genes interact to carry out the cell’s criti-
cal processes. Despite small diﬀerences in study design, the diﬀerent cells
interrogated along with the diﬀerent selection methods show the feasibility
of utilizing the CRISPR-Cas platform as a novel strategy for genome-wide
screens. The diversity of cell lines and cells that typically possess a limited ex
vivo timespan [111], such as primary cells, demonstrates that the method is
applicable in a wide range of contexts, which would provide researchers with
increased possibilities to verify results. Indeed, these studies demonstrate
good knock-out eﬃciency and high targeting specificity. The top hits are
crossvalidated with results from previous screens, paving the way for future
mammalian functional genomics studies investigating a multitude of pertur-
bations and phenotypes. Nevertheless, improvements are still expected, as
the current trend of targeting Cas9 to the 5’ exon of genes does occasion-
ally result in in-frame mutations which does not lead to knock-down and
therefore confounds interpretation of the results. Knock-down eﬃciency has
been shown to vary depending on which domain is targeted, ranging from
a strong gene depletion for some domains to minimal phenotype change for
others [112]. Interestingly, a screen targeting Cas9 only to exon-encoding
domains is an approach to identify drug targets [112]. Screens such as those
discussed above will provide researchers with extensive lists of genes involved
in the processes of interest, requiring validation. An additional step is the
integration of these results with those from other systems-level analyses such
as mRNA profiling, proteomics, and phosphoproteomics in order to obtain a
more complete picture of the mechanisms underlying cellular processes [108].
2.9.2 CRISPR Interference: CRISPRi
The CRISPRi method was developed to allow targeted disruption of gene
expression at the scale of the whole genome [101]. A catalytically dead Cas
mutant retains its ability to recognize DNA sequences when in presence of
sgRNA but lacks cleavage potential and can interfere with gene transcription
via transcriptional elongation, RNA polymerase binding, or transcription
factor binding. CRISPRi is thus reversible, in contrast to CRISPRn, which
utilizes both Cas’ DNA recognition and its cleavage functions and thereby
creates a permanent genetic modification. Additionally, a KRAB repression
domain can be fused to a deactivated Cas9, thereby repressing gene activity
in a targeted manner [113]. A further extension is an inducible version of
CRISPRi, namely dCas9-KRAB, which can be used to reversibly inhibit gene
expression in a tunable manner [114]. Being in possession of the means to
control the expression of nuclease activity is critical to maintaining low but
suﬃcient levels of Cas9 and thereby increasing specificity. Additionally, an
inducible nuclease system can also be utilized to precisely control the timing
of knock-down, which in the case of human induced pluripotent stem cells
has a critical eﬀect on embryonic development and therefore on the outcome
of diﬀerentiation, and that can be used as readout.
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2.9.3 CRISPR Activation: CRISPRa
The CRISPR-Cas system can also be harnessed to perform genome-wide
screens with the aim of identifying novel as well as known genes involved in
a process of interest. While CRISPRi represses gene expression, clustered
regularly interspaced short palindromic repeat activation (CRISPRa) aims
to activate gene transcription by targeted delivery of activators to a gene’s
eﬀector domains [115]. This scalable approach [116] allows modulation of
transcription at the level of the genome. The possibility to perform genome-
wide loss-of-function and gain-of-function screens with the same setup safe
for a diﬀerent sgRNA collection is a powerful tool, since the eﬀect of gene re-
pression and activation can be compared directly and provide complementary
information.
2.9.4 Further Scalable Additions to the CRISPR-Cas Gene
Editing Tool Arsenal
One application of the idea of binding an eﬀector to Cas is for the purpose
of epigenome editing [117]. In this scenario, a nuclease-dead Cas9 is fused
to the catalytic part of human acetyltransferase p300. This allows targeted
acetylation of histone H3K27, thereby activating genes via promoters as well
as proximal and distal enhancers. While several other enzymes make up the
scene of epigenetic control and thus this control is not yet in researchers’
hands, the results are promising. The ability to modulate the presence of
epigenetic markers would provide researchers with another level of control
over gene expression, as well as a precise tool to probe the eﬀect of these
dynamic modifications on cellular phenotype.
2.9.5 In vivo Applications
Animal Disease Models
Beyond in vitro cellular manipulation, gene-editing nucleases have large po-
tential in in vivo applications. One immediate impact is the improved ease
with which it is possible to generate transgenic models of human diseases
in species that were previously diﬃcult to manipulate [59], [60], [118], [119]
as well as for engineering human stem cells [33], providing the means to
directly assess the consequences of gene disruption and of specific muta-
tions. Reporter and conditional mutant mice were created by injecting Cas9
and diﬀerent sgRNAs into zygotes in a one-step procedure. Analysis of oﬀ-
targets in these mice as well as in embryonic stem cells derived from these
zygotes concluded that undesired mutations are relatively rare given careful
experimental design [120]. Similarly, co-injection of early stage monkey em-
bryos has allowed multiplex genetic engineering, and monkeys harboring two
alterations without oﬀ-target mutagenesis have been generated [121]. Fur-
thermore, the complexity of the mutational landscape of patients and the
interplay with disease could be better understood if the generation of ani-
mal models becomes facile to the point of being able to specifically mimic a
patient’s genetic profile [120], [121].
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Gene Therapy
An exciting area of application is the therapeutic field, where targeted nucle-
ases have the potential to reverse disease-related mutations and to disturb or
introduce new genes [122], [123]. The potential thereof is immense, proposing
to correct genetic as well as non-genetic disorders by reversing mutants, re-
placing a gene with a corrected version, or knocking down a deleterious gene.
Zinc-finger nucleases have been applied to correct mutations responsible for
a number of diseases such as sickle cell anemia [124] and others [125], [126].
In addition to the treatment of genetic disorders, preliminary studies have
demonstrated the capability of gene-editing nucleases to inactivate genes or
introduce protective mutations in the case of non-hereditary diseases, for ex-
ample, viral infection. One example is the disruption of the CCR5 receptor in
lymphocytes by NHEJ, which could be used as a therapy for HIV infection.
This and similar approaches have been shown to be possible both with zinc
fingers and TALENs [127] as well as CRISPR-Cas9 [128]. A similar strat-
egy has been applied in a clinical trial where the CCR5 gene was knocked
out ex vivo by ZF nucleases, with successful outcome [129]. The application
of this novel technology in humans as a therapeutic agent will require the
lowest possible number of undesired eﬀects and, therefore, an improvement
in the current tools for the prediction and experimental measurement of oﬀ-
target sites. However, current research has provided tools oﬀering a greater
potential in limiting unwanted oﬀ-target sites, and further specificity could
be aﬀorded by coupling this technology with, for example, nanoparticles,
thereby localizing genetic interventions to tissues of interest. Moreover, the
methods deployed to assess the eﬀects of CRISPR-Cas will need to take into
account the complexity of the human body, and calls for understanding the
systems and interpretation of the findings.
2.10 A Focus on the Application of Genome-Engineering
Nucleases on Chromosomal Rearrangements
One interesting application of CRISPR-Cas technology is the investigation of
chromosomal rearrangements from a systems perspective. These rearrange-
ments are the result of joining of two illegitimate partners at the chromo-
somal level, and are frequently detected in tumors and likely contribute to
cancer progression. Given that these rearrangements have been linked to
breaks in DNA and faulty cellular repair processes, nucleases are an ideal
means to generate DSBs and allow the chromosomal translocations, inver-
sions, or deletions to occur endogenously. Methods developed to assess the
extent of Cas9 oﬀ-target eﬀects are often also capable of profiling chromo-
somal rearrangements due to DSBs [79], [87]; large parts of the framework
needed for this specific application of nuclease-induced gene editing are al-
ready available. In the following sections, we will introduce chromosomal
rearrangements and how they are related to disease, and present what has
been achieved so far (Fig. 2.2).
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Figure 2.2: Diﬀerent types of chromoso- mal rearrange-
ments can be engineered using nuclease based gene editing
tools such as CRISPR-Cas9, e.g. inversions, translocations,
and deletions. Briefly, cells expressing the nuclease and two
guide RNAs are subject to formation of two DSBs, provid-
ing the environment to generate rearrangements. The Cas9
nuclease is targeted to a sequence of interest matching the
guide RNA and possessing a 3’ PAM site.
2.10.1 Introduction to Chromosomal Rearrangements: The
First Disease-Related Translocation
The Philadelphia chromosome was the first chromosomal rearrangement to
be consistently associated with a human disease [130]. In the 1980s, re-
searchers discovered that this abnormally small chromosome was caused by
an interchange between arms of diﬀerent chromosomes, characterizing the
bcr-abl fusion gene [131]. The t(9;22)(q34;q11) translocation, which pro-
duces an oncogenic fusion protein comprised of the N-terminal BCR and
C-terminal ABL1, is now known to be the hallmark of chronic myelogenous
leukemia (CML). The ABL1 non-receptor tyrosine kinase forms a number
of fusion products, which translate into constitutively active tyrosine signal-
ing entities required for cellular transformation [132]. The family of ABL
protein kinases associates extracellular stimuli to signaling pathways gov-
erning essential cellular mechanisms such as cell growth, migration, DNA
damage response, and apoptosis [133]–[135]. Recent studies have demon-
strated activation of ABL family members detected in cancer cells derived
from melanoma, as well as breast, colon, and lung tissue [136]–[138]. The
t(9;22)(q34;q11) chromosomal translocation generates the BCR-ABL1 fusion
protein, which leads to oncogenic activation of ABL1 and deregulated tyro-
sine kinase activity, leading to numerous hematologic malignancies. Several
kinase inhibitors have been developed targeting the tyrosine kinase function
of ABL1, notably imatinib (Gleevec; Novartis), dasatinib (Sprycel; Bristol-
Myers Squibb), and nilotinib (Tasinga; Novartis). Imatinib has been among
the more successful treatments of chronic-phase CML and exerts its eﬀect as
an ATP competitor. ABL1 has been found to be associated with many other
genes forming a variety of fusions, for example, with ETV6, EML1, FOXP1,
and others. Generally, the partners with which ABL kinases associate con-
fer the kinase with increased oncogenicity. This also applies to a number of
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fusions involving tyrosine kinase moieties, where the fusion partner gene can
provide advantageous functionalities, such as targeting the fusion product to
the nuclear pore complex, recruiting additional proteins resulting in a larger
complex [139], recruiting chaperones mediating protein stability [140], and
recruitment of the wild-type form of the partner protein thereby exacerbating
the eﬀect of the rearrangement.
In the decades since the original chromosomal translocation involved in
leukemia was discovered, myriad translocations have been reported and iden-
tified in a number of organs [141]. The unraveling of the BCR-ABL1 story
and the successes of therapies based on it pave the way to a better un-
derstanding of the arising of chromosomal translocations involving kinase
moieties and their impact, as well as to improved drug design in order to
target them.
2.10.2 A Global Look at the Mechanisms behind Chromoso-
mal Rearrangements
The detailed mechanism of chromosomal rearrangements is unknown, but
the etiology of DNA damage [142] and the ensuing repair of thereby induced
DSBs via the NHEJ pathway likely play a large role in the formation of
rearrangements. Chromosomal rearrangements are the consequence of the
inappropriate religation of two DSBs, caused by endogenous or exogenous
sources [143]. Exogenous sources of translocations are ionizing radiation and
cancer chemotherapy [144]. A cell can acquire DNA breaks endogenously in
a number of ways, for example, after exposure to reactive oxygen species,
stalled replication forks leading to free double-strand ends [145], or failure of
sister chromatids to separate properly [146]. Alongside these known causes,
chromosomal fragile sites (nonrandom loci that exhibit gaps and breaks on
metaphase chromosomes following partial inhibition of DNA synthesis) have
long been recognized to act as breakage hotspots [147], [148], and have been
suggested to be associated with carcinogenic translocations [149], [150]. Both
rare and common fragile sites (CFSs) are sensitive to replication stress and
are a hotspot for genetic rearrangements, but the most relevant to cancer are
the CFSs. Common chromosomal sites are present in all individuals, and the
slowing down of replication forks at CFSs as well as a paucity of replication
origins [151] suggests that these sites are indeed particularly vulnerable to
oncogene-induced replicative stress. Studies have confirmed that a small but
significant number of deletions as well as the majority of recurrent cancer-
specific fusions are related to CFSs [152]–[155]. A study by Burrow et al.
[153] determined that, in over half of the gene sets involved in cancer-related
translocations, at least one of two partners possesses a breakpoint located at
a fragile site. Another bioinformatic study [156] concluded that the observa-
tion of breaks occurring preferentially in larger introns is the main significant
feature, consistent with the hypothesis that translocations happen after ran-
dom breakage at fragile sites. However, no specific breakpoint sequence has
been discovered, and no sequence or chromatin features were found to be
significantly enriched in translocated introns after correcting for intron size.
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2.11 A Focus on the Application of Genome-Engineering
Nucleases
Interestingly, the genes participating in translocations showed enrichment in
“DNA binding” and “transcription-factor binding” ontologies (approximately
half of studied translocations compared to 18% in non-translocation-prone
genes). Another noteworthy point is the eﬀect of genome organization on
translocation frequency. Given that DSBs have limited mobility once formed
and that the genome is organized in a nonrandom manner [157], there is
evidence for a correlation between spatial proximity of chromosomes and the
frequency of translocations [158]–[161]. Cell-type-specific genome organiza-
tion provides an explanation for the detection of fusions dependent on tissue
type. However, studies have indicated that in rare cases partners may find
each other over a longer range, suggesting that all translocations may not
be formed following the same system [162]. Single-cell tracking experiments
have shown that the two ends created by the break migrate together and
only dissociate once a partner has been chosen. Once translocation part-
ners find themselves in close proximity, they undergo cycles of pairing and
dissociation and those remaining in close proximity are then candidates for
NHEJ and the formation of a translocation [162]. As mentioned earlier, the
cell possesses various repair mechanisms to handle DSBs, notably homolo-
gous recombination, or NHEJ. Recently it has been shown that NHEJ is the
predominant DSB repair pathway producing chromosomal translocations, in-
deed nearly always leaving alterations at the site of DNA repair [163], [164].
Given the strong ties between gene rearrangements and cancer, an improved
understanding on the underlying mechanisms of rearrangements and a time-
line of the events with respect to disease progression is of great interest, and
the involvement of DSBs makes it an ideal application for the CRISPR-Cas
platform.
2.11.1 Creating Chromosomal Rearrangements Using CRISPR-
Cas
Chromosomal rearrangements can be induced by introducing two DSBs at
distinct sites on the same or on diﬀerent chromosomes [64]–[68], [165], an ideal
application for sequence-specific nucleases. Torres and colleagues proved that
a CRISPR-Cas setup is suitable for creating chromosomal rearrangements;
in separate experiments, they induced two translocation events by directing
Cas9 to cleave the genome at two specific loci for each translocation. Choi et
al. performed similar experiments, showing that not only translocations but
also inversions could be created. Although successful, the frequencies with
which translocations were detected were low, in accordance with estimates
in the occurrence of translocations in vivo [162]. For this reason, both stud-
ies introduced a selective marker before tedious screening of single cells to
detect the desired fusion event. Shortly thereafter, Maddalo and colleagues
successfully induced the EML4–ALK fusion in vivo in mice via adenoviral
infection, and observed the appearance of tumors in infected animals. More-
over, known phosphorylation events typical of the deregulation of the ALK
oncogene were confirmed, thereby supporting the use of this technique to
generate relevant animal disease models. It should be noted that a better
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understanding of the extent to which the alternative fusion products interfere
with the interpretation of results will be necessary for future studies.
2.12 Future Perspectives
From the genome engineering field’s beginnings using recombinant DNA up
to the currently popular technique known as CRISPR-Cas9, it is interesting
to note that most, if not all, approaches have been heavily inspired directly
by already existing biological systems. Continuing basic research will likely
uncover more strategies adaptable for the purpose of biological engineering.
These same ingenious processes are however also subject to the interconnect-
edness and the complex rules governing biological systems. In light of this,
current and future applications of any nuclease-based technology will require
thorough investigation of the eﬀects of its implementation, such as oﬀ-target
nuclease activity. This is relevant both for academic research projects and for
clinical applications, although the impact of the latter is far more apparent.
Indeed, oﬀ-target genetic alterations not accounted for may lead to delete-
rious nonreversible changes, given that nucleases operate at the DNA level.
Furthermore, the ease with which CRISPR-Cas experiments can be designed
makes it an ideal candidate for systems studies, where the whole genome
can be probed with a specific perturbation, for example, drug, stimulus, and
so on. This also obliges the scientific community to recognize that non-
specific side eﬀects must be systematically investigated at a whole-genome
level. Currently, the investigation of chromosomal rearrangements and their
impact is not yet fully scalable and presents new diﬃculties such as the ef-
fects of the remaining possible gene combinations in addition to the desired
rearrangement. Although these have in part been addressed in recent large-
scale studies such as loss-of-function screens, improvements in methods for
the prediction and detection of nuclease-induced gene alterations will allow
increased confidence in the reported results. This is likely to be within rea-
sonable reach in the context of studies such as systems-level gene knockouts.
In addition, the improvement of computational methods for the analysis of
nonlinear oﬀ-target eﬀects will prove critical to deconvolute the results of
systems studies and to aid the therapeutic development of this technology.
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3.1 Abstract
Chromosomal rearrangements are massive genetic events detected across
many blood and solid cancers, both in cultured cells as well as in patients.
While some of their interactors or downstream targets have been investi-
gated, little is known at a systems-level about how they drive cells toward
a cancerous phenotype. Here we used the CRISPR-Cas9 technology to in-
duce double-strand breaks at two chromosomal locations, thereby creating
the conditions necessary for rearrangement. We applied this to generate and
endogenously express the thyroid-specific PRKAR1A-RET fusion in immor-
talized Nthy-ori 3-1 thyroid follicular epithelial cells, increasing the trans-
formative potential of these cells. Mass spectrometry-based analysis found
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that the regulated proteins and phosphosites following fusion induction en-
riched for cancer-related processes, notably regulation of cell cycle control,
MYC and mTOR signaling, EMT and hypoxia. In addition to the processes
identified prior to transformation, the transformed cells also enriched for
apical junctions. These data thus elucidate potential mechanisms by which
the PRKAR1A-RET translocation pushed thyroid cells toward a malignant
phenotype.
3.2 Introduction
Since the discovery of the first chromosomal translocation BCR-ABL1 and
the subsequent success of the ABL tyrosine kinase inhibitor imatinib for the
treatment of chronic myelogenous leukemia, chromosomal rearrangements
involving kinases have been identified across a broad range of blood and
solid tumors. Several of these have been determined to be oncogenic and
identified as driving specific processes related to cancer [1]. Despite their
potential as biomarkers and drug targets, our understanding of the changes
they incur at the level of protein and signaling networks is insuﬃcient to
understand their global impact on cancer cells.
In most kinase fusions retaining functional activity, the kinase moiety is
located C-terminally with respect to the fusion partner. The N-term fusion
partner gene provides the alteration in expression, oligomerization or local-
ization of kinase activity required for oncogenic activity [2]. The frequency
of fusions is tissue-dependent, with thyroid cancers displaying the highest
percentage of recurring kinase rearrangements. Analyses have shown that
fusions with recurrent kinase genes in thyroid cancers are mutually exclusive
with respect to other rearrangements and are thus expected to be key events
in cancer initiation and progression [1].
A large fraction of the research involving gene fusions has been centered
around blood-related malignancies. Moreover, the majority of studies of ge-
netic rearrangements at a larger scale are performed on cells easily amenable
to manipulation and results thus still require validation in a more physiolog-
ically relevant context [3], [4].
Here we examine the eﬀects of the endogenous expression of the thyroid-
specific PRKAR1A-RET translocation in an immortalized thyroid cell line by
investigation of the proteome and phosphoproteome by mass spectrometry.
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) is the most
common kinase fusion moiety in human thyroid cancer, and associates with
PRKAR1A, CCDC6, AKAP13, FKBP15, and NTRK, among others. In the
case of the PRKAR1A-RET fusion (Fig. 3.1, panel a), the genomic break-
point occurs in the intron of the C-terminal partner immediately preceding
the exon coding for the tyrosine kinase domain. Two fusion products can
occur due to alternative splicing of RET: one 52 aa long, the other 9 aa
long (RET portion). The cDNA breakpoint has however been observed to
be identical across many patient tissues, preserving the catalytic activity of
the tyrosine kinase [5].
The spatial organization of chromosomes varies depending on the tissue
of origin, as does the landscape of genetic rearrangements. Indeed, transloca-
tions are preferentially formed when smaller distances separate the two fusion
partners chromosomes [6]. Despite the etiology behind the genesis of these
3.3. Results 69
aberrations not being fully understood, genetic instability likely plays a role,
whether setting the stage for the fusion to occur, or as a result thereof which
would then influence further cellular events leading to disease progression.
These altered dynamics also depend on the specific cellular context, and we
thus introduce the thyroid-specific PRKAR1A-RET fusion in immortalized
thyroid epithelial cells, e.g. rather than in traditionally used NIH3T3 cells
[7].
We used CRISPR-Cas9 technology to create two double-stranded breaks
within the introns of the partner genes reported to harbor the genomic fu-
sion breakpoint [8]–[10]. Following cleavage, rearrangements occur at low
frequency [9]. Importantly, this method for generation of chromosomal rear-
rangement allows for an endogenous expression level of the resulting fusion
product, which we expect to lead to a cellular system displaying protein
and signaling dynamics with increased resemblance to a physiological setting
(Fig. 3.1, panel c), essential for the interpretation of events leading to a
cancerous phenotype.
In addition to improving our understanding of how kinase rearrange-
ments alter the proteomic and signaling state of cells, we address whether
the endogenous expression of the fusion product is capable of triggering the
transformative process. We assess anchorage-independent growth using a
soft agar assay, as well as used this as a means for selection of subclones to
determine the changes required for malignant transformation. Proliferation
in the absence of anchorage has been shown to correlate with tumorigenicity
[11]. These colonies were cultured briefly thereafter and cells harvested in
order to investigate the altered cell state required for transformation.
3.3 Results
3.3.1 Induction of the PRKAR1A-RET chromosomal rear-
rangement
To identify and quantify the protein concentration and signaling changes
induced upon expression of the thyroid-specific PRKAR1A-RET transloca-
tion, we used a label-free mass spectrometry approach. Because normal
human epithelial cells senesce after only a few divisions in culture we used
SV-40 immortalized non-transformed thyroid cells (Nthy-ori 3-1 [12]) that
are suitable for cell culture, but have low colony formation ability and are
non-tumorigenic in mice.
The fusion of intron 7 of PRKAR1A (exons 1 through 7) and intron 11
of RET (exons 12 through 20) leads to a fusion product of 596 amino acids
in length, retaining the regulatory and cyclic NMP binding domains of the
N-terminal PRKAR1A and the full tyrosine kinase domain belonging to the
C-terminal RET kinase (Fig. 3.1, panel b). CRISPR-Cas technology was
used to generate two double-strand breaks at the intronic locations corre-
sponding to the identified breakpoint thereby allowing the chromosomal re-
arrangement to occur. Cas9 and the selected guide RNAs (HA, HB, TA, TB)
were virally transduced in thyroid cells (Fig. 3.2), and Cas9 cleavage activity
was induced (Fig. 3.1, panel c). Endogenous DNA repair led to the formation
of fusions at low frequency, thereby generating a mixed population of cells.
From these mixed populations we selected cells containing the fusion by single
cell cloning. We screened clones for the fusion by PCR using cDNA primers
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Figure 3.1: a The translocation formed by the fusion of
PRKAR1A and RET genes. The chromosomal breakpoint
(shown in red) was situated in introns of chromosomes 17 and
10, respectively. b SMART domain prediction for the pro-
tein product of the fusion described in a. The Regulatory
subunit portion of type II PKA R-subunit (RIIa) and the
cyclic nucleotide-monophosphate binding domain (cNMP)
domains of PRKAR1A were fused N-terminally with the in-
tact tyrosine kinase domain of RET. c depicts the main steps
in detail leading to the generation of cells used for subsequent
mass spectrometric analyses.
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surrounding the breakpoint. Due to the requirement of a PAM sequence for
directed Cas9 cleavage, the intronic breakpoint did not exactly correspond to
the breakpoint reported in tissue samples. However, the resulting cDNA and
therefore expressed protein sequence was identical to the sequence reported
previously. Four combinations of guide RNAs were transduced targeting the
intronic breakpoint region (HATA, HATB, HBTA, HBTB), two of which
(HATB, HBTB) generated fusion-positive clones. Cell populations derived
from three single cell clones corresponding to each of the two successful guide
RNA combinations were chosen for further experiments, resulting in a total
of 6 fusion-expressing clones, named here HATB_1, HATB_2, HATB_3,
HBTB_1, HBTB_2, HBTB_3. After identification of successful fusion ex-
pression, protein was harvested for mass spectrometry-based sampling of the
rewired network upon expression of the rearrangement product.
After normalization of peptide intensities based on linear regression, repli-
cates were combined and peptide ratios to Cas9-transduced cells (ThyCas9)
were analyzed using a Markov Chain Monte Carlo framework to determine
protein concentration and phosphosite occupancy ratios along with a measure
of uncertainty. From this analysis we identified 5’456 quantifiable proteins,
and 9’723 unique phosphorylated sites, mapping to 2’742 proteins carrying
a phosphosite. We subjected proteins and sites quantified over all samples
to hierarchical clustering using a Euclidian distance metric shown in in Fig.
3.2. For both the identified proteins and phospopeptides we observed distinct
clustering of the fusion-expressing cells compared to the control cells. The
remarkably similar signal observed in each fusion-expressing cell line would
suggest that chromosomal rearrangements drive quantifiable yet conserved
changes at the cell signaling level.
3.3.2 Protein expression and signaling in cells expressing PRKAR1A-
RET
We found 1’208 of the quantified proteins (22.1%) to be significantly regu-
lated (z-score 1.2) in cells containing the PRKAR1A-RET fusion compared
to the control (z-score 1.2). Overall, we observed a shift toward diﬀerential
downregulation (797 proteins) compared to upregulation (448 proteins).
We compared our regulated proteins to proteins found to be important in
thyroid cancer [13]. Within this set we identified TPR (previously observed
to fuse with MET in thyroid cancer), KTN1 (highly expressed in thyroid
cancer compared to other cancer types), TPM3 (a tumor suppressor gene),
ERC1 (related to the NF- B pathway), and NRAS (frequently mutated
oncogene). Interestingly several of these (TPR, KTN1, TPM3, ERC1) have
been detected as rearrangement partners in thyroid cancer. This is in line
with the observation that thyroid cancer displays a high number of fusions
in comparison to other solid tumor cancers.
3.3.3 Predicted PPI
We next wished to address whether our network of identified and regulated
proteins faithfully replicated the eﬀect of the fusion in thyroid cancer. Given
the dearth of systematic studies of gene fusions, the downstream changes as
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Figure 3.2: a shows the protein concentration log ratio to
ThyCas9 cells for all cells expressing the fusion as well as the
original Nthy-ori 3-1 cells. b shows phospho-site occupancy
log ratios for the same sample set as in a. Only proteins or
sites seen in all samples are represented here.
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Table 3.1: Predicted interactors of PRKAR1A-RET
(ChiPPI) found to be significantly regulated upon fusion ex-
pression. Bold font denotes the tumor suppressor genes
within the overlap. Italic denote known oncogenes. (**)
denotes proteins with phosphosite regulation.
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well as the interactors of the PRKAR1A-RET fusion are not well character-
ized. The ChiPPi database addresses this issue by predicting the protein-
protein interactions of a fusion based on known preferential interaction of
protein domains and their co-occurrence and thus predicts the resulting af-
fected proteins [14]. Following this strategy, predictions suggest interactions
may be gained (oncogenes) or lost (tumor suppressors) upon fusion expres-
sion, leading to a more cancerous cellular state. ChiPPI predicted 111 unique
interactions of the parental genes (here PRKAR1A and RET) to be aﬀected
by the generation of the fusion. Of these, we identify 70 (63%) in our dataset,
73% of which are also identified the phosphorylation data. Furthermore, of
the predicted proteins identified in the concentration data 15 showed diﬀer-
ential expression in our dataset (z-score 1.2) when comparing changes in the
cells containing the fusion compared to the ThyCas9 cells (Table 3.1). Of
the 15 regulated proteins that were also predicted to be aﬀected, 4 (26.6%)
were tumor-suppressor genes (ChiPPI predicted 20 TSGs to be modulated).
We identified 5 out of the 8 protein-protein interactions predicted to be lost
upon expression of the fusion, with none of these being significantly regulated
in cells containing the fusion. Two of the predicted altered interactors also
showed significant phosphosite regulation. The overall agreement of our data
with that of predicted changes due to this fusion consolidated our confidence
in the dataset.
3.3.4 Fusion expression leads to enriched hallmarks
In order to determine whether the observed signaling network changes driven
by PRKAR1A-RET fusion were related to oncogenesis we assigned functional
annotations using the hallmark gene set collection of MSigDB, based on
coherently expressed genes representative of biological processes [15]. We
compared the regulated proteins and phosphoproteins in cells carrying the
fusion to ThyCas9 cells in terms of their hallmarks. We found that proteins
regulated in cells harboring the fusion were extremely highly enriched for
MYC targets (FDR = 3.37x10-111) (Fig. 3.3). The overexpression and
amplification of MYC is involved in the majority of human cancers and leads
to the acquisition of cancer hallmark characteristics such as uncontrolled
proliferation. We also observed a high enrichment for proteins upregulated
by mTOR related signaling (FDR = 3.06x10-71), which have been shown
to aﬀect cell proliferation, viability as well as iodide uptake in thyroid cells
[16]. Several other processes central to cancer were found to be strongly
regulated in our dataset: oxidative phosphorylation (FDR = 3.03x10-42),
targets of E2F transcription factors (FDR = 1.85x10-35), genes involved in
the G2/M cell cycle checkpoint (FDR = 3.96x10-32), epithelial-mesenchymal
transition (FDR = 8.57x10-24), as well as hypoxia (FDR = 6.88x10-21).
Enrichment for genes regulated by E2F transcription factors as well as the
G2/M cell cycle checkpoint are both indicative of changes occurring at the
level of the cell cycle, crucial to the cancer cell’s ability to sustain uncontrolled
growth. Epithelial-mesenchymal transition is a major mechanism involved
in tumor progression and has been reported to be activated in anaplastic
thryoid carcinomas [17].
Perhaps surprisingly we identified only 54 significantly modulated phospho-
proteins following expression of the PRKAR1A-RET fusion, which could be
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linked to the nature of the experiment. Indeed, after the formation of the re-
arrangement following nuclease-mediated double-strand breakage, the fusion
product was under the control of the endogenous promoter of the 5’ translo-
cation partner. This is in contrast to studies where the fusion construct is
constantly (over)expressed and therefore unsurprisingly elicits high levels of
signaling. We nevertheless sought to investigate the nature of the regulated
phosphosites.
Regulated phosphosites showed an enrichment for similar processes as
diﬀerentially regulated proteins with MYC targets (FDR = 1.22x10-7), E2F
targets (p-value = 8.63x10-5), the G2/M checkpoint (FDR = 8.63x10-5),
protein secretion (FDR = 1.92x10-4) and epithelial-mesenchymal transition
(FDR = 1.62x10-3).
3.3.5 Cells expressing fusion show increased anchorage-independent
growth
To determine if the fusion induced malignant transformation, the 6 fusion
cell lines and control cells (original and transduced with Cas9) were tested
in a soft agar colony formation assay, and the extent of colony formation
was assessed after 2 weeks of growth in agarose. We observed a signifi-
cant increase in colony formation potential in several of the cells expressing
the PRKAR1A-RET rearrangement: HATB_3, HBTB_1, HBTB_2 and
HBTB_3 as compared to control cells (Fig. 3.4).
3.3.6 Transformed cells with fusion exhibit diﬀerential regu-
lation
We next determined protein expression and signaling changes in cells that dis-
played anchorage-independent growth, which has been reported to correlate
with tumorigenesis. To do so, we picked colonies and subsequently expanded
them in culture for 2 passages to generate suﬃcient protein for proteomic
and phosphoproteomic analyses. In order to separate fusion-specific eﬀects
from growth in soft agar, control cells (Nthy-ori 3-1) having formed smaller
but clear colonies underwent parallel sample handling (Fig. 3.2).
As was the case for the non-transformed cells, we sought to compare
regulated proteins in our data with proteins previously reported as relevant
to thyroid cancers. We identified regulation of TPR in fusion-expressing
colonies. We also identified modulation of HMGA1 expression in transformed
cells. Previous studies have shown that elevated HGMA1 and HGMA2 levels
are required for transformation of thyroid cells. [18]. Also known to be
involved specifically in thyroid cancer and showing diﬀerential phosphosite
regulation in transformed cells were KTN1, ERC1 and PCM1. As is the case
for KTN1 and ERC1, PCM1 has been also been found rearranged in thyroid
cancers, although in this case to RET [19].
3.3.7 Cells homozygous for fusion increasingly enrich for can-
cer hallmarks
During single cell cloning we noted that two of the six clones (HBTB_1
and HBTB_3) had a shorter doubling time in culture. These two clones also
showed the largest increase in their ability for anchorage-independent growth
compared to control cells. Although sequencing of the clones confirmed the
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Figure 3.3: Strongly enriched cancer hallmarks and possi-
ble mechanisms in which the PRKAR1A-RET fusion could
exert its eﬀects. Solid lines link network nodes that have
been observed as regulated by mass spectrometry. Dashed
lines correspond to edges involving not observed proteins.
a and b show the genes regulated in non transformed cells
upon fusion expression associated with upregulation of E2F
and mTORC1, respectively. c depicts the genes upregulated
under hypoxic conditions that were regulated in non trans-
formed fusion-harboring cells. d Phosphoproteins regulated
in transformed cells were enriched in genes mediating apop-
tosis. e Genes encoding for the apical junction complex were
found to be enriched specifically in transformed cells.
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Figure 3.4: Soft agar colony formation assays to as-
sess anchorage-independent growth of fusion-expressing cells.
Left to right: Percent intensity and percent area of the assay
area covered by colonies, respectively. Box plots summarize
data obtained from triplicate repeats where control cells did
not express the PRKAR1A-RET fusion.
presence of the fusion in all selected cases, we noted an increase in the noise
level for the four clones which did not show a decreased doubling time (Supp.
Fig. 3.3). This could be due to the selection of a mixed population at the
moment of single-cell cloning. While the HBTB_1 and HBTB_3 clones are
clearly homozygous for the translocation, we can only speculate that the
other clones might be cases of heterozygosity.
We therefore wished to assess the processes aﬀected in the cells with
potentially the most aggressive fusion phenotype and retained HBTB_1
and HBTB_3 as representative fusion-containing cells and colonies of these
clones. The 743 regulated proteins in this subset enriched for similar pro-
cesses as the non-transformed cells. As was the case prior to transformation,
the most enriched hallmarks were MYC targets (FDR = 1.12x10-41), E2F
targets (FDR =1.05x10-25), oxidative phosphorylation (FDR = 1.82x10-23),
upregulated proteins related to mTOR signaling (FDR = 3.16x10-20), G2/M
checkpoint (FDR = 2.69x10-13) and protein secretion (FDR = 5.21x10-10).
In contrast to the non-transformed cells, we identified an enrichment for
genes upregulated by reactive oxygen species (ROS) (FDR = 1.56x10-11). In
vivo, inflammatory cells can release ROS, which are deleterious for neighbor-
ing cancer cells. Genes regulated as a consequence of the presence of reactive
oxygen species are known to drive cells toward a malignant phenotype [20].
We also noted proteins associated with the formation of apical junctions
(FDR = 1.23x10-10) to be enriched. This is likely a key shift allowing cells
to exhibit anchorage-independent growth and thus for their transformation.
Indeed, epithelial cancers often display loss of cell-cell adhesion and cell po-
larity in order to gain in plasticity, leading to increased invasiveness [21].
Interestingly we found notably more altered phosphorylation in the colonies
than we did the fusion expressing cells. We identified 404 significantly modu-
lated phospho-proteins compared to the ThyCas9 cells. These were enriched
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for MYC targets (FDR = 4.36x10-39), E2F targets (FDR = 1.59x10-26),
G2/M checkpoint (FDR=5.81x10-19), and upregulated proteins related to
mTOR signaling (FDR =3.74x10-10). As was the case for diﬀerentially ex-
pressed proteins, modulated phosphosites enriched for proteins associated
with the formation of apical junctions (FDR=2.51x10-7), suggesting that
this hallmark is specific to the transformed state. We noted that regulated
phosphoproteins in the colonies carrying the fusion were also enriched in
apoptosis, which is often suppressed in cancers (FDR=2.28x10-9).
3.4 Discussion
To the best of our knowledge, this study represents the most extensive sam-
pling of the proteomic and phoshoproteomic network changes upon endoge-
nous expression of a chimeric gene found in solid tumors. We identified and
quantified many changes occurring in cells following the endogenous expres-
sion of the fusion. We confirmed the regulation of several genes known to be
involved in thyroid cancers. Furthermore, our analysis showed that cells har-
boring the induced fusion enriched for processes essential for tumorigenesis.
Notably, we identified enrichment for genes involved in regulating the cell
cycle, critical for uncontrolled proliferation and the most prominent cancer
hallmark. We also noted increased regulation of MYC and mTOR targets,
whose implication in a large number of cancers is well-established.
After demonstrating that the PRKAR1A-RET fusion caused increased
malignant transformation in immortalized thyroid cells, we showed that the
regulated proteins and phosphosites further enriched for cancer hallmarks.
We observed a large overlap of enriched properties compared to non trans-
formed cells, albeit with higher enrichment in transformed cells. Strikingly,
we observed the appearance of apical junctions as a marker for cells in a
transformed state following fusion expression. We speculate that this is an
important mechanism by which cells may acquire changes related to adhesion
and migration, and potentially invade their surroundings during tumorigen-
esis.
Rearrangements have now been identified in myriad diﬀerent solid tu-
mor cancers and have been shown to be able to confer cells harboring them
increased malignant behavior. However with the exception of studies in-
vestigating blood-related diseases, there are few experimental systems-wide
studies of the eﬀect of chromosomal translocations. In silico predictions of
rewired protein-protein interactions upon fusion expression suggest that there
are commonalities in the general signaling mechanisms of fusions that lead
to cancer [14]. The overlap of our regulated proteins with the predictions of
aﬀected interactors was therefore encouraging, and the work presented here
is a direct validation of several of these predictions.
We believe it is of the utmost importance to study the eﬀects of such
perturbations in a context as close as possible to the physiological setting.
Indeed, many studies investigating RET rearrangements in thyroid cancer
were performed in non-thyroid cells. Moreover, the majority use a viral or
plasmid vector to introduce the fusion construct in cells. These are generally
expressed under strong promoters and thus might lead to an expression of
the translocation which does not reflect in vivo conditions. While these have
provided critical insights into the targets and mechanisms of the fusion, the
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results are likely confounded by the aforementioned limitations. Here we have
therefore created a model to study PRKAR1A-RET expressed at endogenous
levels in a non-transformed thyroid cell line, mimicking conditions in which
the fusion would arise.
To consolidate the findings presented here, we propose to induce the fu-
sion in primary cells and assess its potential for full transformation. Beyond
gleaning an improved understanding of the mechanisms of the expressed fu-
sion product, the ultimate aim would be to determine the role of the kinase
fusion during transformation to assess its use as a druggable target for the
treatment of cancer.
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3.7 Materials and Methods
3.7.1 Cell lines and vectors
SV40 immortalized primary cells (n-thy-ori) from thyroid follicular epithe-
lial tissue were purchased from Sigma and cultured in RPMI 1640 medium
supplemented with 2 mM glutamine, 10% FBS, 1% antibiotic-antimycotic
solution (all Gibco) in a humidified environment with 5% CO2. HEK-
293T cells were cultured in DMEM, supplemented with 10% PBS and 1%
penicillin/streptomycin. pCMV-VSV-G, psPAX2, pCW-Cas9 Dox-inducible
lentiviral vector and pLX-sgRNA lentiviral vector containing AAVS1-targeting
sgRNA from Addgene.
3.7.2 Viability assay
Cells were seeded at 4e5 cells/well in growth medium in 6-well tissue culture
plates. Media was substituted with increasing concentrations of puromycin
the following day and was maintained for 3 days, after which growth media
was given for 3 days to allow potential recovery/resistance. Cells were washed
3 times with PBS and stained with a Crystal Violet solution for 30 minutes
followed by several PBS washes.
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3.7.3 Vector construction
The pLX-sgRNA vector was digested with Xba1, Nde1 for 2 hrs at 37C, ran
on a 0.5% agarose gel followed by gel extraction and purification. The DNA
digest was further used to clone a new vector allowing for facile insertion of
sgRNA oligonucleotides via Gibson reactions. In order to select for successful
transduction of the second sgRNA, the vector was further modified to replace
the blasticidin resistance with hygromycin.
3.7.4 Determination of targeted breakpoint location
The empirically observed breakpoint of the translocation event was verified
using COSMIC [22] and ChiTars [23] and the introns selected by following the
principle of last observed- and first observed exons given several documented
cases of the same translocation, with varying numbers of exons detected in
the partner genes. Only one combination of introns targeted for CRISPR-
Cas9-mediated cleavage was retained, using the intron following the last seen
exon of the head partner and the intron preceding the first observed exon of
the tail moiety.
3.7.5 Lentiviral sgRNA design
The tool developed by Doench et al. was used to score all SpCas9 Proto-
spacer Adjacent Motif (PAM) sites within selected introns. The two top-
scoring guide sequences were retained for each translocation partner. A ’G’
was prepended to the guide sequence (GX20 sgRNA), with the benefit of di-
minishing oﬀ-targets at the cost of cutting eﬃciency [110]. Top-scoring guide
sequences were verified by submission to Zhang et al. web-tool. Selected sgR-
NAs were verified with updated oﬀ-target prediction algorithm GUIDE-seq
[24].
3.7.6 HEK-293 infection
2e6 HEK-293T packaging cells were seeded in a 75cm2 cell culture flask in
growth medium without antibiotics. The following day, cells were trans-
fected with pCMV-VSV-G, psPAX2, and pCW-Cas9 vectors using MirusBio
TransIT-LT1 transfection reagent, and after 24 hours media containing high-
BSA was substituted. 24 hours later media was harvested and residual cells
were removed by filtration.
3.7.7 Viral pCW-Cas9 transduction and titration
Nthy-ori 3-1 cells were seeded at 300’000 cells/well in a 6-well plate. The
following day, protamine sulfate was added to flasks to a final 8 µg/ml and
cells were transduced with the Cas9 construct with increasing volumes of
virus-containing harvested media : 0, 2, 5, 10, 20, 50, 75, 100, 150, 200, 250
µL. After overnight incubation, growth media was replaced.
Cells with increasing viral titers were seeded in 96-well tissue culture
plates at 5000 and 10000 cells/well in 200 µL of media. Growth media
was replaced with medium supplemented with 0.8 µg/mL puromycin the
following morning. Alamar Blue was added to the wells and % viable cells
was measured at 570 nm after 5 hours and after 24 hours. The lowest viral
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titer at which cells were viable post selection was chosen to move forward,
and cells were further maintained in puromycin-containing media.
3.7.8 Dosing of doxycylin as Cas9-inducing agent
4e5 Thy-Cas9 cells were sparsely seeded in 10cm dishes and the following
morning doxycycline was added at 1 µg/mL in each dish (previous assay
showed 1µg/mL to show suﬃcient activity). Cells were harvested every 24
hours in duplicates or triplicates in Laemmli sample buﬀer followed by West-
ern Blot analysis. Cultures without doxycycline were maintained and lysed
in parallel as negative controls. Analysis by immunoblot showed peak Cas9
expression at 72 hours followed by a decline to barely detectable activity
after one week.
3.7.9 Viral modified pLX-sgRNA transduction
Media containing viral sgRNA vectors was harvested as previously described
for each individual sgRNA. 1e6 Thy-Cas9 cells were seeded per 25 cm2 cell
culture plate. The following morning harvested media was added to growth
media in increasing volumes, at equal volumes between the two sgRNAs
of a given combination. Cells were split twice and selected for 14 days in
media supplemented with 0.8 µg/mL puromycin, 10 µg/mL blasticidin or
200 µg/mL hygromycin. The condition with lowest viral volume mediating
resistance was retained for further experiments.
3.7.10 Cas9 expression induction
Doxycycline at a final concentration of 1 µg/mL was administered for 1 week
to 4e5 cells seeded in 100mm tissue culture dish. Doxycycline-containing
media was refreshed after 4 days. Immediately thereafter individual clones
were generated via single cell cloning using clonal rings and were expanded
(96-well was named "p1 after single cell cloning").
3.7.11 Translocation detection PCR
RNA was extracted using Qiagen RNA extraction kit from cells at various
passages following single cell cloning. Clones were screened for translocations
and the cDNA breakpoint determined by RT-PCR in a 96-well AB Veriti Fast
Thermal Cycler using the Quantitect SYBR green RT-PCR kit (Qiagen) at
the following the manufacturer’s guidelines and using an annealing tempera-
ture of 56C for 30 s, and extension at 72C for 60 s, and a final extension of 5
min at 72C. The forward primer was AGACAATGGCCGCTTTAGCCA and
the reverse primer was CAGGGAGCCGTATTTGGCGT. Sanger sequencing
was used to confirm sequence of bands at correct weight 3.3.
3.7.12 Anchorage-independent growth assay
Transformation was verified using the soft agar colony formation assay [25].
6-well tissue culture plates were coated with growth medium containing 1%
agarose, and triplicate dishes were inoculated with 10’000 or 2’000 cells sus-
pended in RPMI-1640 containing 0.8% agarose and 15% FBS, for count-
ing and colony picking, respectively. Colony formation was assessed after 2
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weeks. Image analysis was done using ImageJ, with plugins ColonyArea [26]
and ColonyCounter (https://imagej.nih.gov/ij/plugins/colony-counter.
html).
3.7.13 Mass spectrometry lysis and sample preparation
Protein was harvested by lysing a 150 mm dish at 80-90% confluency in 1 mL
modified RIPA buﬀer (50 mM Tris pH 7.5, 150 mM NaCl, 1% NP-40, 0.5%
Na-deoxycholate, 1 mM EDTA) supplemented with phosphatase inhibitors (5
mM þ-glycerophosphate, 5 mM NaF, 1 mM Na3VO4) and protease inhibitors
(Roche cOmplete ULTRA Tablets, EDTA-free, #05892791001), sonicated,
and spun down for 20 min at 4300G. Ice-cold acetone was added to the su-
pernatant to achieve a final concentration of 80% acetone, and protein was
left to precipitate overnight at -20 . Precipitated protein was pelleted by
centrifugation at 1800G for 5 min and solubilized in 6 M urea, 2 M thiourea,
10 mM HEPES pH 8.0. Protein was quantified using the Bradford assay
and 650 µg of each sample were reduced with 1 mM DTT, alkylated with 5
mM ClAA, and digested with endopeptidase Lys-C (1:200 v/v, Wako #129-
02541) for 3 hours. Samples were diluted to 1 mg/mL protein using 50
mM ammonium bicarbonate and incubated overnight with trypsin (1:200
v/v, Sigma #T6567). Digested samples were acidified and urea removed
using Sep-Pak tC18 96-well plate (Waters #186002320) C18 cartridges. An
aliquot of 50µg of eluted peptides was set aside for proteome analysis as
well as peptide quantitation (Pierce quantitative colorimetric peptide assay,
Thermo #23275) to equalize injection load for label-free LC-MS/MS analy-
sis. The remainder was lyophilized, aliquots of 200µg made up in 1 M glycolic
acid, 80% ACN, 5% TFA, and enriched for phosphopeptides using MagReSyn
Ti-IMAC beads (#MR-TIM010 ReSyn Biosciences) following the manufac-
turer’s protocol. Enriched peptides were subjected to a final C18 clean-up
prior to data acquisition.
3.7.14 MS data acquisition
All spectra were acquired on an Orbitrap Fusion Tribrid mass spectrometer
(Thermo Scientific) operated in data-dependent mode coupled to an EASY-
nLC 1200 (Thermo Fisher Scientific) liquid chromatography pump and sepa-
rated on a 50cm reversed phase column (Thermo, PepMap RSLC C18, 2µM,
100Å, 75µmx50cm). Proteome samples (non-enriched) were eluted over a
linear gradient ranging from 0-11% ACN over 70 min, 11-20% ACN for 80
min, 21-30% ACN for 50 min, 31-48% ACN for 30 min, followed by 76%
ACN for the final 10 min with a flow rate of 250 nL/min. Phosphopeptide-
or phosphotyrosine enriched samples were eluted over a linear gradient rang-
ing from 0-18% ACN over 195 min, 18-26% ACN for 30min, 26-76% ACN
for 10min, followed by 76% ACN for the final 5 min with a flow rate of 250
nL/min.
Survey full scan MS spectra were acquired in the Orbitrap at a resolution
of 120000 from m/z 350-2000, AGC target of 4e5 ions, and maximum injec-
tion time of 20 ms. Precursors were filtered based on charge state (  2) and
monoisotopic peak assignment, and dynamic exclusion was applied for 45s.
A decision tree method allowed fragmentation for ITMS2 via ETD or HCD,
depending on charge state and m/z. Precursor ions were isolated with the
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quadrupole set to an isolation width of 1.6 m/z. MS2 spectra fragmented by
ETD and HCD (35% collision energy) were acquired in the ion trap with an
AGC target of 1e4. Maximum injection time for HCD and ETD was 200 ms
for phosphopeptide-enriched samples, and 80ms for proteome samples.
3.7.15 Fasta file generation
DNA was extracted from the MDA-MB 231 cell line at 80% confluence using
the Qiagen QIAamp DNA Mini kit, according to the manufacturers’ instruc-
tions. Sequencing was performed by Beckman Coulter Genomics with a tar-
get average exome coverage of 89x. We filtered the reads with Trimmomatic
[27] with the following parameters: headcrop = 3, minlen = 30, trailing =
3. We aligned the trimmed reads to the hg19 reference genome with BWA
[28], applied GATK [29] base quality score recalibration, indel realignment,
duplicate removal, and performed SNP and INDEL discovery and genotyping
across all samples simultaneously using standard hard filtering parameters
according to GATK Best Practices recommendations [30]. We used the En-
sembl Variant Eﬀect Predictor (VEP) [31] with Ensembl v. 75 to predict
the eﬀect of the mutations on the protein sequence. In order to find non-
reference, mutated peptides in the MS data, we increased the search Fasta
file with mutations aﬀecting the protein sequence detected by WES with a
high sensitivity filter: QD  1.5, FS   60, MQ   40, MQRankSum  -12.5,
ReadPosRankSum  -8.0, and DP at least 5 / sample on average.
3.7.16 Mass spectrometry identification and quantification
All label-free raw data were searched using MaxQuant v1.5.1.2 against the
human Ensembl database (v88), the mutant proteins from exome sequencing
as well as the sequence of the fusion product [32]. Default settings were used
with the exception of a minimum peptide length of 6 amino acids. STY
phosphorylation was added as a variable modification. An FDR of 0.01 was
applied at the level of proteins, peptides and modifications. Phosphosites
were filtered for a localization score of at least 0.9.
3.7.17 Data analysis
All data analysis was carried out in R, with additional packages [33]–[38].
Label-free quantification (LFQ) was performed based on extracted ion chro-
matograms (XIC) for identified peptides after retention time alignment by
MaxQuant. XICs were normalized per peptide. Log ratios used throughout
were taken to the ThyCas9 control.
3.7.18 Markov Chain Monte Carlo
A likelihood function for each concentration c or phosphorylation occupancy
o ratio was calculated as follows:
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Supplementary Figure 3.1: FLAG-tagged Cas9 expres-
sion optimization. The lowest dose of doxycycline showing
suﬃcient Cas9 expression was selected for further experi-
ments. Expression of Cas9 peaks 72 hours after induction
and decreases thereafter, indicating requirement to replenish
doxycyclin-supplemented media for induction periods longer
than 3 days.
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where xˆ is a vector of the peptide ratios mapped to the protein, I and t are
indicator matrices of size i⇥s reporting whether peptide i spans phosphosite
s (I) or is modified on site s (t), and ⌫ and   are Bayesian variance parameters
established by fitting Beta distributions by binned absolute log ratios. We
sampled this likelihood for each protein separately with Bayesian Markov
Chain Monte Carlo (MCMC) with Jeﬀrey priors on o and o0 with ↵1 = ↵2 =
1
2 , and an exponential prior with   = 2 on c.
Finally we calculated the means and standard deviations of the chains,
resulting in means and standard errors for each protein and phospho-site
occupancy. We calculated phosphosite ratios for a given sample to the control
as log(o.sample/(1  o.sample))  log(o.reference/(1  o.reference)).
3.7.19 Functional enrichment analyses
The hallmark gene sets of the Molecular Signatures Database (MSigDB) were
used to determine enriched hallmarks.
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Supplementary Figure 3.2: Viability assay for the deter-
mination of viral titer for lentiviral transduction in n-thy-ori
cells.
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Supplementary Figure 3.3: cDNA PCR to identify ex-
pression of fusion product in single cell-derived clones. The
red rectangle denotes the overlapping region between the
gene pair, PRKAR1A and RET.
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4.1 Summary
The acquisition of an invasive phenotype is the first step in the development
of metastatic potential, and we therefore aimed to identify signaling processes
implicated in migrating cells. We used high-throughput LC-MS/MS to quan-
tify the modulation of phosphorylation in triple negative breast cancer cells
upon wounding. The tyrosine and serine/threonine phosphoproteome was
sampled at frequent and extremely early time points(ranging from several
seconds up to one hour) in order to generate detailed temporal signaling
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profiles per phosphorylated residue. A large portion of the quantified phos-
phoproteome was found to be regulated at the earliest measured time points
(sub-minute range), showed an increase in tyrosine phosphorylation, and spe-
cific sites were found to be enriched for cell motility. The increased ability of
proteins harboring modulated phosphosites to aﬀect migration was confirmed
using siRNA-mediated knockdown, showing a change in cell migration veloc-
ity. This study identifies a number of currently unannotated phosphorylation
sites potentially involved in wound healing and migration, suggesting their
potential as novel class of metastatic-reducing drug targets.
4.2 Keywords
Proteomics, wound healing, cell signaling, phosphorylation, cancer
4.3 Significance
Current specific cancer therapies are developed to act upon kinases by com-
peting for their ATP-binding site, thus decreasing their ability to phospho-
rylate their substrates and thus interrupt signal transduction. We identify
distinct phosphorylation sites within a single protein to be implicated in dif-
ferent cellular processes. This suggests that, although sometimes successful,
targeting the active site of kinases is likely to lack specificity in terms of the
targeted process. In order to target cell migration and therefore possibly
reduce metastatic burden in cancer patients, we believe that rendering phos-
phosites inactive could be suﬃcient to control disease. Over time, as our
knowledge of the precise cellular events in which phosphorylation sites are
involved improves, this information may be used in research to develop more
intricate models of cellular signaling, as well as for the development of novel
therapeutics.
4.4 Highlights
• Breast cancer cell monolayer wounding resulted in immediate signaling
response
• Very early temporal signaling dynamics showed an increase in tyrosine
phosphorylation
• Modulated phosphorylation signaling was associated with migration
• Novel targets for anti-metastatic therapies identifed by modulated sig-
naling peptides
4.5 Introduction
"Tumors are wounds that do not heal" [1]. A link between cancer and wound
healing processes has been thought to exist since observations of similarities
between tumor stroma and tissue at the site of healing skin wounds, sug-
gesting that common molecular mechanisms might underlie the two events.
Cellular processes responsible for wound healing are complex and tightly
modulated in order to restore tissue at the site of injury. The wound-healing
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process and carcinogenesis share the following processes: inflammation, cell
proliferation, migration and invasion. Although certain cancers may activate
this latent wound-healing program to modify connective tissue as needed for
their sustained growth, they lack the regulation of the normal wound re-
pair process and as a consequence uninhibited cell proliferation and invasion
ensue.
Inflammation was found to be required for wound-related tumor forma-
tion at sites of injury [2]. Indeed, several cancers are known to arise directly
as a result of a chronic inflammatory response, such as that caused by Heli-
cobacter pylori infections and irritable bowel syndrome. [3]. Inflammation is
a hallmark of cancer and is critical for disease progression [4], [5], providing
a framework for sustenance of the inflammatory response as well as gener-
ating reactive oxygen species (ROS) which in a cancer setting may aﬀect
DNA repair mechanisms and are thought to contribute to enhanced malig-
nant transformation [6]. Following wounding, cells at the edge of the wound
exhibit directed migration in order to fill the void at the site of injury, pro-
viding another parallel to cancerous cells.
One of the earliest events in the metastatic process is the invasion of cells
located in the primary tumor into their environment. Increased migratory
and invasive ability is therefore an important characteristic for malignant
cells and for their metastatic potential [7]. Metastasis is responsible for the
majority of breast cancer patient deaths, rather than primary tumors, which
in many cases can be surgically removed.The ability of tumor cells to generate
metastases being an early event in the development of cancer, patients would
benefit from treatments preventing or limiting the dissemination of malignant
cells early on. Thus targeting the migratory phenotype is an interesting
avenue for the improvement and development of novel tumor-suppressing
treatments.
The migratory process relies on spatial and temporal signaling dynam-
ics, for instance when interacting with the extracellular matrix (ECM) or
signaling via growth factor receptors resulting in individual or collective cell
movement [8], [9]. Gene expression studies have shown a regulatory response
within 30 minutes of injury to murine or human tissue followed by hundreds
of regulated genes a few hours thereafter [10], [11]. However, many essen-
tial events participating in cellular responses are a result of post-translational
protein modification dynamics rather than changes in gene expression or pro-
tein abundance. In terms of the signaling mechanisms themselves, a phos-
phorylation response can occur within seconds of a perturbation [12], which
can be studied using a time course data set. Several studies [13]–[15] have
investigated changes in the phosphoproteome at early time points in response
to cues such as growth factor stimulation, some as early as 5 seconds after
perturbation.
Here we address the question of how cells sense injury from a signaling
perspective and decide on directed cell migration in order to fill the void
left following wounding. We propose to detect very early signaling dynamics
following wounding, and aim to identify mechanisms involved in the earli-
est stages of the inflammatory response and leading to migration into the
wound. As a model for response to wound healing and cell migration, we use
an in vitro wound healing assay [16] applied to a confluent monolayer of the
triple-negative breast cancer cell line MDA-MB-231 known to be invasive in
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mouse models [17]. The scratch assay provides a model system to under-
stand cell migration dynamics, also taking into account cell-cell interactions
and their impact on overall migration into the gap. Currently, mechanistic
insight regarding the way cells incorporate and process signals and how this
is translated into cellular outcomes remains obscure. We sample the cellular
phosphoproteomic networks for a series of time points, and we expect to help
elucidate the overall signaling and system dynamics and provide a starting
point for hypotheses requiring more in-depth targeted experimental design.
To study the signal transduction mechanisms involved using high- through-
put global mass spectrometry, we enrich for tyrosine- as well as serine/threonine
(Ser/Thr)-phosphorylated peptides from cells harvested at the earliest fea-
sible time points and regularly up to one hour following scratching, totaling
10 time points. Given the small size of scratches (2x4 mm), we expected the
fraction of the cell population sensing the perturbation to be relatively small,
and therefore designed our study to maximize the phosphorylation signal re-
lated to wound sensing, while minimizing the response typically involved
with sample handling-related stress [18]. Practically speaking, this was done
by using a 384-well pin tool to reproducibly create 384 scratches in every tis-
sue culture plate, thereby increasing the number of cells at the wound edge.
Additionally, in order to capture these early cellular phosphorylation events,
we snap froze cell monolayers in liquid nitrogen and immediately proceeded
to lysis, thereby reducing confounding ischemia-driven signaling events.
We hypothesized that there exist several layers of complexity in the earli-
est response to scratching, and that cells experience these responses at diﬀer-
ent time points as a function of their distance to the wound. Our data display
a very early upregulated phosphosite regulation occurring within minutes of
wounding predominantly related to cell adhesion. Thereafter, a second large
wave of activated signaling around 16-30 minutes occurs. We will present
this dataset and point to the known cellular processes we have identified to
be enriched within the very early response at the signaling level.
4.6 Results
4.6.1 Immediate phosphosite modulation upon wounding
As a model for response to wounding, we used the MDA-MB-231 breast
cancer cell line and wounded the cell monolayer. Wounds closed 16 to 24
hours after scratching indicating that the closing of the wound is due to
migration rather than proliferation (MDA-MB-231 cells have a doubling time
of approximately 30 hours [19]). We therefore focused our study to the first
hour post wounding in order to identify the signaling network changes which
occur directly after wounding and that cause the initiation of the migratory
response. In total, cells were harvested at 10 time points after wounding
: immediately after scratching (denoted as "0", since this is the earliest
feasible time point), 30 s, 45 s, 1 min, 2 min, 4 min, 8 min, 16 min, 30
min, and 1 h (Fig. 4.1). In order to preserve the phossphorylation state
within cells [20] and to quench signaling at precise timepoints, we snap froze
cells within seconds (approximately 5 s) following wounding. We believe
this step to be critical, as most signaling related studies contain time-courses
beginning after at least several minutes following perturbation, and are likely
overlooking early signaling dynamics.
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Figure 4.1: General illustration of the experimental work-
flow. a shows the full time-course for a putative phospho-
peptide. The y-axis represents the log ratio of any given time
point to the control : unwounded cells at 0 h. b depicts the
lysis steps in detail as well as the subsequent proteomic work-
flow. Cell monolayers on tissue culture plates are immersed
into liquid nitrogen for 3 s in order to retain the signaling
state of cells.
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Cells unwounded at 0 h served as controls, and the ratio of each time
point to the control will be referred to as the label-free log fold change of a
given peptide or protein throughout this study. After normalization of high
confidence phosphopeptide ratios based on a linear model to account for small
loading discrepancies, time-course data was fit using a Gaussian process to
infer log ratios and the standard deviation for missing time points, which
resulted in a total of 3333 phospho site temporal profiles, corresponding to
1768 proteins. Time-courses with significant variation with respect to the
mean (variance > 0.005) were retained and denoted as being dynamically
modulated. The sites with lower variation were classified as either "con-
stantly modulated" if there was a significant fold change at all timepoints, or
"unmodulated" in the case of temporal profiles that varied neither over time,
nor compared to the non-wounded cells. The 1085 dynamically modulated
temporal profiles were subjected to hierarchical clustering using a Euclidian
distance metric 4.2. We observed a relatively small fold change compared to
the control (Fig. 4.2), which may suggest that the wounding signal impacts
a small number of cells most likely at the wound edge.
4.6.2 Dynamically modulated phosphoproteins exhibit dis-
tinct temporal activation profiles
The subset of peptides that were dynamically modulated could be further
classified using hierarchical clustering to generate time-dependent signaling
patterns based on the modulation of phosphopeptides normalized to their
mean response over all tested timepoints. Seven clusters were derived by the
dendrogram, and these were grouped into four temporal signaling trends, for
which representative profiles are illustrated in the right panel of Fig. 4.2:
"early" denotes 560 unique phosphopeptides with increased modulation at
the earliest measurable time-point following wounding, and remained acti-
vated until approximately one to two minutes. "Mid" contains 85 unique
phospho-peptides that displayed increased modulation at approximately two
minutes, after which the signal returned to baseline. The "late" group con-
tains 440 unique phosphorylated peptides showing significant modulation
only at later timepoints, i.e. several minutes after wounding. Thus, over
half of the varying sites were already modulated at the earliest measured
time point. For simplicity, this time point was called "0", but in reality
corresponds to approximately 5 seconds after wounding.
In over 24% of cases profiles of distinct phosphosites on the same protein
fall in at least two diﬀerent temporal clusters, thus displaying diﬀerential reg-
ulation, a phenomenon that has also been noted by others [21]. For example,
in the case of EGFR, Tyr-1197 falls into the early cluster, Ser-1166 into the
"mid" cluster, and Tyr-869 and Thr-693 show regulation in the latest time
points. As observed in Olsen et al., we detect tyrosine phosphorylation of
EGFR to be upmodulated first, followed by activation of EGFR serine and
threonine sites at later time points.
An additional example is MAPK1, a mediator of EGFR signaling, which
was found to have modulated phosphopeptides belonging to diﬀerent clusters.
Phosphorylation at Tyr-187 is activated at "0" minutes, with a peak at 30
seconds before decreasing steadily. Thr-185 appears in the "mid" cluster,
with a clear peak at 2 minutes, followed by a gradual decrease to slightly
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Figure 4.2: Heatmap representing the diﬀerent signaling
trends following cell monolayer wounding. 1085 phospho-
peptides (vertical) whose ratio to the control (top left color
key) showed variation over time were subjected to hierarchi-
cal clustering. Their corresponding temporal profiles are dis-
played horizontally. Clusters were generated by cutting the
dendrogram at a height of 1.5, resulting in seven phosphosite
subsets (denoted by colored dendrogram branches). These
were then further classified into three groups representing
early, mid, or late dynamics. The plots to the right of the
heatmap show illustrative temporal profiles for the phospho-
sites in the corresponding "activation clusters". The dotted
line corresponds to the non-varying phosphosites that were
not used for hierarchical clustering.
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Figure 4.3: Regulatory information mapped from the
PhosphoSitePlus database. Significantly enriched processes
are shown for sites dynamically modulated (orange bars),
sites constantly modulated (blue bars) as well as unmodu-
lated sites showing low or no variation (grey bars). P-values
were obtained by applying Fisher’s exact test to sites map-
ping to processes in PhosphositePlus.
lower than pre-activation levels. Both sites are known to induce cell motility
and growth.
4.6.3 Functional analysis of modulated phosphopeptides fol-
lowing wounding
Next we investigated the biological relevance of these phosphosites, by map-
ping to functionally annotated sites in the PhosphositePlus database [22].
Although over 77% of our phosphosites have been observed in the literature,
the majority of the sites lack curated functional annotation, with only 3.3%
of our phosphosites mapped to a known function.
Despite the low coverage of functionally annotated sites, we observed
several significantly enriched processes as shown in Fig. 4.3. Strikingly, the
top cellular process identified in the dynamically modulated phosphosites was
induced cell motility. Indeed, the enrichment of phosphosites for increased
cell motility was dramatic in comparison to non dynamically modulated sites.
Cytoskeletal reorganization, apoptosis, cell growth and cell diﬀerentiation,
were all also enriched in the dynamically modulated group.
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4.6.4 Modulated phosphosites enrich for genes aﬀecting wound
closure
We further validated the functional relevance of phosphorylated proteins by
investigating the eﬀect of knocking down their corresponding genes using
RNA interference on the velocity of cells after wounding. Interestingly only
the modulated sites enriched for genes aﬀecting cell velocity (p-value mod-
ulated sites: 0.017, p-value constantly modulated sites: 0.065, and p-value
unmodulated sites: 0.703). Similarly phosphosites that were functionally an-
notated in PhosphositePlus as aﬀecting cell motility or adhesion were also
targeted with siRNA knockdown (Table 4.1). Of the 9 proteins that did not
have modulated phosphosites, 33% significantly aﬀected velocity post wound-
ing. In contrast, of the 16 tested proteins that had dynamically modulated
phosphosites 9 (56%) significantly aﬀected cell velocity. Several of these
function as signal transducers (EGFR, MAPK1, MAPK3, MPZL1, STK24,
PRKCD) MAPK1 and MAPK3 are both modulators of EGFR signaling,
and STK24 is a regulator of the JNK pathway. CD44 (related to invadopo-
dia formation), CTNNA1 (component of adhesion complexes), and MYH9
(focal adhesion, cytoskeletal re-organization) are involved in the adhesive
properties of cells.
4.6.5 Dynamically modulated phosphoproteins enrich for ty-
rosine kinases
Olsen et al. determined the proportion of tyrosine phosphorylation to make
up approximately 1.8% of phosphorylated peptides. In our study peptides
which did not change over time displayed a similar distribution of phosphory-
lated amino acids: 2.1% on tyrosine, 7.9% threonine and 90.0% serine, indeed
close to previously reported tyrosine phosphorylation proportions. However,
the phosphopeptides that were dynamically modulated showed an increase of
phosphorylation on tyrosine residues, with 4.4% of sites being tyrosine, 11%
threonine, and 84.8% serine residues. Table 4.2 lists the modulated tyrosine
phosphosites and their corresponding gene names. Many of these tyrosine
phosphorylated proteins are clearly migration-related, such as actin, Actinin
alpha 1, Dynein light chain LC8-type 1 , Copine 1 and Plastin 3.
We further noted that proteins with tyrosine phosphorylation signifi-
cantly aﬀect velocity upon siRNA knock-down, underlining the importance
of tyrosine phosphorylation in cellular communication and the migration pro-
cesses. Of relevance additionally in the group are the tyrosine kinases which
have in many cases been found to be overexpressed or mutated and lead to
oncogenic states [23]. In particular we note EPHA2, which has been identi-
fied as a target for chemotherapy in the case of triple negative breast cancer.
[24]. Finally, the tyrosine phosphorylation of p53 is noteworthy due to its
established role as a tumor suppressor, but also due to its involvement in
metastasis [25]. In addition to our p53 aﬀecting cell velocity, exome sequenc-
ing of the MDA-MB-231 cells revealed the presence of the R280K oncogenic
mutation in the p53 gene [26].
4.6.6 Functional analysis of proteins following wounding
As noted there are relatively few curated functional annotations in the Phos-
phosite Plus database. Gene Ontology (GO) biological process enrichment
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Table 4.1: Table of genes associated with phosphosites
functionally annotated with migration in PhosphoSitePlus.
Genes aﬀecting velocity are marked with a star (*). Genes
with a p-value lower than 0.005 are considered to aﬀect the
velocity of MDA-MB-231 cells upon knock-down. Delta ve-
locity represents the change in migration speed [pixel/hour]
compared to the siRNA non-targeting control.
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Table 4.2: Table of tyrosine-phosphorylated sites dynam-
ically modulated over time and their corresponding genes.
Proteins in bold font are tyrosine kinases. Genes marked
with a star were found to aﬀect velocity of migrating cells
upon knock-down. Delta velocity represents the change in
migration speed [pixel/hour] compared to the siRNA non-
targeting control.
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Figure 4.4: Left barplot: Gene Ontology Biological Pro-
cesses significantly enriched in dynamically modulated sites
(orange), and unmodulated sites (blue). No enriched pro-
cesses were found to be significant in the group of constantly
modulated phosphosites. Right barplot: For each process,
the enrichment for number of genes significantly aﬀecting ve-
locity is shown. P-values were obtained from Gene Ontology
enrichment analysis with a background genome comprised of
genes detected in the unscratched cells.
analysis was therefore carried out on the genes corresponding to activated
phosphosites involved in the various modulation clusters (Fig. 4.4). Cell-
cell adhesion was the biological process with the largest activation in early
time points and increased compared to the non-varying peptides, and thus
confirmed that the phosphopeptides showing early signaling dynamics are
indeed related to relevant processes as a result of the applied perturbation.
Adhesion-related processes will be discussed further in subsection 4.6.7. Ad-
ditional interesting processes were viral processes (potentially linked to an
inflammatory response following perturbation), mRNA processing, splicing
and export, translational initiation, as well as processes related to metabolism
such as gluconeogenesis, and canonical glycolysis. For each process display-
ing enrichment (left barplot, Fig. 4.4), the enrichment for the number of
genes significantly aﬀecting velocity is shown (right barplot, Fig. 4.4). Dy-
namically modulated sites involved in cell-cell adhesion were twice as likely
to aﬀect velocity compared to sites in unmodulated or constantly modulated
clusters. Genes confirmed to aﬀect velocity are listed in Table 4.3.
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4.6.7 Signaling Localization
The site modulation groups described above showed changes in the location
of signaling activity as a function of their modulation after wounding (left
barplot, Fig. 4.5). Supporting the previous results, the dynamic modulation
response showed enrichment for clear migration-related cellular components
such as cell-cell adherens junctions (p-value: 5.16x10-16), focal adhesion (p-
value: 6.83x10-13), the extracellular matrix (p-value: 1.29x10-6), and cell-cell
junctions (p-value: 1.84x10-3). First-line eﬀectors of migration via their role
in adhesion (cell-cell adherens junctions, focal adhesions, cell-cell junctions)
showed an enrichment of genes aﬀecting velocity. Additionally, components
known to be involved in the migratory response were also found to be en-
riched in the dynamically modulated group, such as signaling in extracellu-
lar exosomes (p-value: 8.64x10-14), actin cytoskeleton (p-value: 1.17x10-6),
the membrane and plasma membrane (respectively, p-value: 5.78x10-9 and
p-value: 5.88x10-4), and the cell cortex (p-value: 1.16x10-4). As for the pro-
cesses, the enrichment for the number of genes significantly aﬀecting velocity
is shown (right barplot, Fig. 4.5).
Interestingly, the unmodulated group of phosphosites displayed an en-
richment in GTPase and Rho-related signaling when considering biological
processes (Fig. 4.4). Diverse roles have been reported for the proteins of the
Rho family, being at the same time responsible for cell motility via the cre-
ation of novel sites of adhesion as well as focal adhesions disassembly [9]. We
noted that in Fig. 4.4, the processes related to GTPase and Rho signaling
also displayed the most dramatic enrichment in genes aﬀecting velocity upon
knock-down. Furthermore, the categories for which this observation was also
true in terms of cellular components (Fig. 4.5) was for the cell cortex and
cytoskeleton. We therefore speculate that these might be linked. Velocity
hits associated with significant GO processes are listed in Table 4.4.
Cell-cell adhesion was found to very strongly enriched for the dynamically
modulated cluster genes (p-value: 1.67x10-12). In terms of cellular location,
this would be expected to translate into signaling at cell-cell adherens junc-
tions, which were also significantly enriched (p-value: 5.16x10-16).
We also observe regulation of phosphorylation on proteins neighboring
cadherin complexes, such as tight junction proteins TJP1 and TJP2, which
play a role in tight junctions as well as adherens junctions. Tight junctions
provide a barrier function between cells and are placed apically in such a
manner as to create tight seals between cells. Adherens junctions are placed
just beneath the tight junctions, closer to the basal end of the cell. Together,
these junctions form junctional complexes. Proteins such as TJP1 and TJP2
are thought to provide a scaﬀold for the placement of tight junctions with
respect to other junctions [27].
We have shown that in our measurement of very early signaling we ob-
served increased signaling at adherens junctions, as well as altered cell motil-
ity. One explanation for this could be that following wounding, the loss of
neighboring cells with adhesions causes the cells to trigger migration in order
to repair the wounded area and reconstitute the cell monolayer.
As seen in the processes in Fig. 4.3, the activated phosphosites were en-
riched for induction of cell motility compared to non-varying phosphosites.
Acquisition of motility is known to be one of the first steps undertaken by
cells in the process of migration and ultimately, of the genesis of metastases.
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Figure 4.5: Gene Ontology Cellular Components signif-
icantly enriched in the dynamically modulated group (or-
ange) and compared to unscratched cells. Processes were
found to be enriched only in the group of dynamically mod-
ulated phosphosites. For each component, the enrichment
for number of genes significantly aﬀecting velocity is shown.
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In order to achieve this goal, actin polymerization is required for cell po-
larization and elongation. In our data, signaling at the actin cytoskeleton
(p-value: 1.17x10-6) was enriched in the modulated phosphosite group. The
enrichment of cytoskeletal reorganization throughout the time-course (Fig.
4.3) could be due to the fact that elongation and assembly of actin is required
in the early events of migration as well as during the next step : formation of
focal adhesion. Then, focal adhesions (signaling enriched in modulated group
with p-value: 6.83x10-13) are formed with the ECM (p-value: 1.29x10-6), as
a requirement for contraction and movement of the main cell body [8]. Reg-
ulation of focal adhesion and cell migration can be mediated by diﬀerent
integrins depending on cell type, as well as other proteins such as CD44 or
matrix metalloproteinases. Although we do not observe integrin regulation
in this dataset, we do observe regulation of CD44 S706 in the early cluster, as
well as a steady increase of non-modified CD44 over time. CD44 is known to
mediate cell-cell and cell-matrix interactions via binding of hyaluronic acid,
which in turn plays an important role in cell migration and promotion of
metastasis, but not in the initiation of tumorigenesis [28]. Although focal
adhesions are durable junctions, formed when there is ample time for strong
attachment to a surface, our data does not suggest an increase in the for-
mation of focal adhesions within minutes, but rather an increase in signaling
detected at already existing focal adhesions at the sub-minute time-scale.
4.6.8 Extracellular matrix
The adherens and tight junctions described earlier mainly concern connec-
tions and communication between cells, allowing cells to transmit signal fol-
lowing a perturbation such as wounding. Another important event in relation
to migration is the contact between cells and extracellular elements, typically
mediated by integrins attached to actin filaments via talin proteins. In our
data, we observe an initial dip of TLN1-S620 followed by steady increase over
time. Moreover, in our data signaling modulated in the extracellular matrix
was found to be rich in structural proteins (LMNA, MYH9, VIM, FLNA,
FLNB).
Integrin signaling results in PTK2 activation, located downstream of sev-
eral other growth factor receptors. PTK2, also known as focal adhesion
kinase (FAK), can in turn regulate the AKT1 and the MAPK pathways,
as well as promoting phosphorylation of SRC and BCAR1, among others.
We observe regulation of PTK2 at several sites the dynamically modulated
group. Moreover, phosphorylated BCAR1 sites show an increase in early
time points. It should be noted that these events could also be the result of
EGFR activation.
Interestingly, we also observed an enrichment in dynamic signaling in
extracellular exosomes (p-value: 8.64x10-14), which allow for the transport
of molecules from the cell to the extracellular space, and thus bilateral reg-
ulation of the cancer cell and the extracellular matrix surrounding it. We
observed regulation of sites on kinases associated with extracellular exosomes,
e.g. MAPK1, MAPK3, PRKAR2A, AXL, PRKCA, PRKCD.
Studies have identified an abundance of exosomes from cancer cells, and
proteins contained in these exosomes can alter target cells or the microenvi-
ronment by transferring the oncogenic properties of the primary cell [29].
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4.6.9 Discussion
To the best of our knowledge, this set of time points is the first and most
extensive mass spectrometry-based phosphoproteomics dataset studying the
early response to wounding. Previous studies investigating wound response
have been based mainly on transcriptomics [10], [11], with time points start-
ing several minutes after wounding. Olsen et al. described signaling dynam-
ics downstream of EGFR using SILAC in combination with phosphopeptide
enrichment. Indeed, the well-established SILAC workflow provides accurate
quantification allowing precise determination of fold-changes upon perturba-
tion. We show that reliable quantification of fold-changes upon perturbation
is also feasible using label-free quantification in a phosphoproteomic dataset,
which we have used to detect biologically relevant signaling trends.
Here we have demonstrated a strong enrichment for migration-associated
phosphorylated proteins in dynamically regulated phosphosites and thus the
validity of this dataset as a resource. However, many of the studied proteins
that were identified as modulated at the level of their phosphorylation state
are not recognized to have a role in relation to wound healing or migration.
We believe that a number of the dynamically modulated sites lacking func-
tional annotation at the level of their phosphorylation are also implicated in
migratory or invasive processes with mechanisms remaining to be uncovered
by further studies.
This dataset, although rich, suﬀers from an intrinsic property of most
LC-MS/MS-based proteomics studies, in that the output is an average of
a population of cells, and the spatial information we can gain is limited.
Imaging methods (e.g. immunofluorescence, laser ablation coupled to mass
cytometry) would provide the means to understand the directionality of the
signal traveling away from the wound, as well as to observe protein dynam-
ics within cells upon phosphorylation. This would allow further dissection
of the signaling that appears to be unmodulated in this study: the total
amount of the phosphorylated form of a given peptide may appear constant,
while a change in e.g. cellular localization may increase its signaling impact.
For further validation studies of this dataset, we will investigate the spa-
tial dynamics of the modulated phosphorylation signal using imaging mass
cytometry [30].
We recognize that due to the nature of the experimental setup the signal-
ing presented here might be a distorted rendering of the normal physiological
setting in the context of wounding. However, the very early modulation of
signaling enriching for known migration-related processes and the confirma-
tion thereof with our knock-down experiments in associated genes indicate
that the regulation we observe is relevant to the study of migration of cancer
cells. It should be noted that the type of cell motility assay may have an
impact on the result and could thus be at least partly responsible for the
importance of cell adhesion observed in this dataset. Indeed, cells are more
dependent on adhesion in 2D assays such as the one used in this study com-
pared to 3D cultures where cells are in contact with the extracellular matrix,
thus providing other means of migrating.
In this work we demonstrate the feasibility of identifying novel phospho-
rylation sites in relation to the migratory response following wounding using
high-throughput assays such as mass spectrometry. As touched upon earlier,
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there is a paucity of phosphorylated residues with known functional annota-
tion, limiting our prediction of mechanisms governing migration-related sig-
naling. Utilizing antibody fragments specific to phosphorylation sites coupled
with imaging akin to our knock-down assessing change in velocity, it would
be possible to determine if these sites are aﬀecting migration, and thereby
work toward improving our functional knowledge of phosphorylation. As an
illustration of this, we detect various phosphosites on EGFR to be modu-
lated diﬀerently over the time course studied here. Impairing the function of
each of these phosphosites separately or in combinations may lead to distinct
phenotypic outcomes. Perhaps more importantly, these regulated sites may
represent a pool of drug targets currently not taken advantage of. Indeed,
most therapeutics aimed at kinases physically block the ATP binding site.
Blocking specific sites of phosphorylation could be envisaged as an alterna-
tive means of intervention, for instance using site-specific antibodies. Given
the centrality of signaling in migration, it is reasonable to ask whether tar-
geted interference with phosphosites might be a strategy for the development
of metastasis-decreasing therapeutics.
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4.10 Materials and Methods
4.10.1 Cell culture
MDA-MB-231 cells were grown in DMEM-F12 (1:1) media for SILAC (Thermo
#88215) supplemented with Pen/Strep (Gibco, #15140-122) and 10% dial-
ysed fetal bovine serum (Sigma #F0392). In preparation for the wound assay,
a constant number of cells were plated in rectangular tissue culture dishes
(Nunc, 165218) in order to create reproducible scratch patterns. Cells were
allowed to reach close to confluency for 48 hours, were serum-starved for 24
hours, after which serum was re-introduced. 24 hours after ending serum
starvation, the cell monolayer was scratched using either a 96-pin (late time
points: t=8min and upwards) or 384-pin tool (early time points: t=0 until
4min) (V&P, 96 and 384 wounding tools, with pins #FP3-WP). When using
the 96-pin tool, 4 scratches (2mm X 4mm) were made in close succession
amounting to a total of 384 scratches. Reproducible scratching was ensured
by using a pin guide tailored to the culture dishes (designed & produced
in-house).
4.10.2 Sample preparation
Immediately after scratching, media was replaced with fresh serum-free me-
dia (if early) or with serum-containing media (later time points). After the
desired time elapsed, cells were washed with serum-free media, and placed
in liquid nitrogen in order to rapidly quench cellular activity. On ice, cells
were scraped oﬀ plates into a modified RIPA buﬀer (50 mM Tris pH 7.5, 150
mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 1 mM EDTA) supplemented
with phosphatase inhibitors (5 mM  -glycerophosphate, 5 mM NaF, 1 mM
Na3VO4) and protease inhibitors (Roche cOmplete ULTRA Tablets, EDTA-
free, #05892791001), sonicated, and spun down for 20 min at 4300G. The
time series samples were processed on the same day and replicates were cre-
ated weeks apart repeating the same procedure, due to the amount of protein
lysate required for proteomic analyses. This likely resulted in a decreased cor-
relation between replicates. Ice-cold acetone was added to the supernatant to
achieve a final concentration of 80% acetone, and protein was left to precipi-
tate overnight at -20 . Precipitated protein was pelleted by centrifugation at
1800G for 5 min and solubilized in 6 M urea, 2 M thiourea, 10 mM HEPES
pH 8.0. Protein was quantified using the Bradford assay and 24 mg of each
sample were reduced with 1 mM DTT, alkylated with 5 mM ClAA, and di-
gested with endopeptidase Lys-C (1:200 v/v, Wako #129-02541) for 3 hours.
Samples were diluted to 1 mg/mL protein using 50 mM ammonium bicar-
bonate and incubated overnight with trypsin (1:200 v/v, Sigma #T6567).
Digested samples were acidified and urea removed using SepPak (Waters
#WAT020515) C18 cartridges. Peptides were eluted, an aliquot of 100µg set
aside for proteome analysis, and the remainder dried by lyophilization, before
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resolubilization in commercial IAP buﬀer for phospho-tyrosine peptide en-
richment, following the manufacturer’s indications (Cell Signaling, #8803).
Phospho-tyrosine enriched peptides were eluted and cleaned up using C18
StageTips (3M Empore, #66883-U).
Unbound peptides from the immunoprecipitation were retained and di-
luted ten-fold before being put through SepPak C18 cartridges. Eluates were
made up to 80% ACN, 6% TFA and TiO2 beads (GL Sciences, #5020-75010)
in loading buﬀer (0.02 g/mL Dihydroxybenzoic acid, 30% CH3CN, 4% TFA
(or: 0.13 M Dihydroxybenzoic acid, 30% CH3CN, 4% TFA)) were added
at a 1:1 w/w ratio with peptides, and the peptide-bead slurry was rotated
end-over-end at RT for 30 minutes. Unbound peptides were collected for a
second and third enrichment using TiO2 microspheres. Beads were washed
three times with 60% ACN, 1% TFA, transferred to a C8 96-well plate (3M
Empore, #6314), and phosphopeptides were eluted sequentially with two
elution buﬀers: 5% NH4OH, followed by 10% NH4OH, 25% ACN. Eluates
were combined and cleaned up using C18 StageTips.
Peptides from proteome and phosphoproteome samples were quantified
using the Pierce quantitative colorimetric peptide assay in order to stan-
dardize final loading amounts. Samples were lyophilized and equalized in
1% formic acid (FA) to same loading amounts for label-free quantification.
Immediately prior to injection, spike-in peptide standards (Sigma, MSP1H)
were added to each sample for normalization purposes with a final on-column
load of 33 fmol. Due to the lower amount of peptides expected following phos-
photyrosine enrichment, these samples were not quantified but their volumes
were equalized prior to MS analysis. Due to the nature of label-free quan-
tification, standardized conditions were achieved by processing samples in
parallel, as well as monitoring of chromatographic and mass spectrometric
conditions over time using a complex digest of HeLa cells.
4.10.3 MS data acquisition
All spectra were acquired on an Orbitrap Fusion Tribrid mass spectrometer
(Thermo Scientific) operated in data-dependent mode coupled to an EASY-
nLC 1200 (Thermo Fisher Scientific) liquid chromatography pump and sepa-
rated on a 50cm reversed phase column (Thermo, PepMap RSLC C18, 2µM,
100Å, 75µmx50cm). Proteome samples (non-enriched) were eluted over a
linear gradient ranging from 0-11% ACN over 70 min, 11-20% ACN for 80
min, 21-30% ACN for 50 min, 31-48% ACN for 30 min, followed by 76%
ACN for the final 10 min with a flow rate of 250 nl/min. Phosphopeptide- or
phosphotyrosine enriched samples were eluted over a linear gradient ranging
from 0-18% ACN over 195 min, 18-26% ACN for 30min, 26-76% ACN for
10min, followed by 76% ACN for the final 5 min with a flow rate of 250
nL/min.
Survey full scan MS spectra were acquired in the Orbitrap at a resolution
of 120000 from m/z 350-2000, AGC target of 4e5 ions, and maximum injec-
tion time of 20 ms. Precursors were filtered based on charge state (  2) and
monoisotopic peak assignment, and dynamic exclusion was applied for 60s.
A decision tree method allowed fragmentation for ITMS2 via ETD or HCD,
depending on charge state and m/z. Precursor ions were isolated with the
quadrupole set to an isolation width of 1.6 m/z. MS2 spectra fragmented by
ETD and HCD (35% collision energy) were acquired in the ion trap with an
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AGC target of 1e4. Maximum injection time for HCD and ETD was 200 ms
for enriched samples, and 80ms for proteome samples.
4.10.4 Fasta file generation
DNA was extracted from the MDA-MB 231 cell line at 80% confluence using
the Qiagen QIAamp DNA Mini kit, according to the manufacturers’ instruc-
tions. Sequencing was performed by Beckman Coulter Genomics with a tar-
get average exome coverage of 89x. We filtered the reads with Trimmomatic
[31] with the following parameters: headcrop = 3, minlen = 30, trailing =
3. We aligned the trimmed reads to the hg19 reference genome with BWA
[32], applied GATK [33] base quality score recalibration, indel realignment,
duplicate removal, and performed SNP and INDEL discovery and genotyping
across all samples simultaneously using standard hard filtering parameters
according to GATK Best Practices recommendations [34]. We used the En-
sembl Variant Eﬀect Predictor (VEP) [35] with Ensembl v. 75 to predict
the eﬀect of the mutations on the protein sequence. In order to find non-
reference, mutated peptides in the MS data, we increased the search Fasta
file with mutations aﬀecting the protein sequence detected by WES with a
high sensitivity filter: QD  1.5, FS   60, MQ   40, MQRankSum  -12.5,
ReadPosRankSum  -8.0, and DP at least 5 / sample on average.
4.10.5 Mass spectrometry identification and quantification
All label-free raw data were searched using MaxQuant v1.5.1.2 [36] against
the human Ensembl database (v88), as well as the MDA-MB-231 specific
proteins from exome sequencing. Default settings were used with the excep-
tion of a minimum peptide length of 6 amino acids. STY phosphorylation
was added as a variable modification. An FDR of 0.01 was applied at the
level of proteins, peptides and modifications. Phosphosites were filtered for a
localization score of at least 0.9. Data processing was carried out in R, with
additional packages [37]–[42].
4.10.6 Markov Chain Monte Carlo
A likelihood function for each concentration c or phosphorylation occupancy
o ratio was calculated as follows:
L(c, o¯, o¯0) = logP (z¯|µ¯(c, o¯, o¯0))
=
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(4.1)
where xˆ is a vector of the peptide ratios mapped to the protein, I and t are
indicator matrices of size i⇥s reporting whether peptide i spans phosphosite
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s (I) or is modified on site s (t), and ⌫ and   are Bayesian variance parameters
established by fitting Beta distributions by binned absolute log ratios. We
sampled this likelihood for each protein separately with Bayesian Markov
Chain Monte Carlo (MCMC) with Jeﬀrey priors on o and o0 with ↵1 = ↵2 =
1
2 , and an exponential prior with   = 2 on c.
Finally we calculated the means and standard deviations of the chains,
resulting in means and standard errors for each protein and phospho-site
occupancy. We calculated phosphosite ratios for a given sample to the control
as log(o.sample/(1  o.sample))  log(o.reference/(1  o.reference)).
4.10.7 Gaussian Process Regression
Individual protein concentrations and phosphorylation occupancies fromMarkov
Chain Monte Carlo peptide integration were calculated for each replica set
of MS experiments. The time point values X (concentration and occupancy)
were considered gaussian random variables. For each protein and phospho-
site at separate time points the mean value and standard error of the MCMC
chains after burn-in constituted the data expectation value X and variance
 X2.
Given the non-linear time intervals in the MS data a new unit time was
assigned to the ordered time points. Before modeling, the time series were
normalized by subtracting the series mean value X(t). Only series with more
than one time point were kept for modeling.
Gaussian Process Regression (GPR) [43] was used to model each time
series as a function of unit time given the observed data
P (t) = GPR(t|X(t), X(t)).
This Bayesian approach allowed modeling the data and noise collectively,
and enabled posterior predictions via the chosen prior kernel. The kernel
hyper-parameters (general noise level and length scale) were optimized with
respect to the GPR log-marginal likelihood using the L-BFGS-B algorithm
[44]. The best model of three random initialized runs within the parameter
constraints was chosen. Time series imputation of all missing data points
was performed with the optimized GPR function P (t) to produce complete
time series including noise estimates.
4.10.8 Prior Kernel
The prior used was a sum of a squared exponential kernel [43] and a general
noise component as a (’white kernel’)
k(xi, xj) = exp
✓
 1
2
d(xi/l, xj/l)
2
◆
+ k(noise|xi = xj).
where d is the euclidian distance and l is the length-scale parameter for
the exponential part of the kernel, and reports on the similarity between con-
secutive points. It must be positive (l > 0) and is fitted during optimization.
The white kernel was constrained to the range [min( X(x)2),max( X(x)2)].
The prior covariance matrix was initialized at the diagonal with the data
noise  X(x)2. The squared exponential kernel length scale was constrained
to [1, 2] time units.
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4.10.9 Functional enrichment analyses
Gene Ontology categories with an FDR <5 were considered, and p-value <
0.05 was used as significance measure. Calculation of enrichment for pro-
cesses in PhosphositePlus was done using Fisher’s exact test and p-values <
0.05 were considered significant. Calculation of enrichment of genes aﬀect-
ing velocity was done using Fisher’s exact test and categories with an odds
ratio > 1 were deemed significant. All analyses were carried out using the R
programming language[37].
4.10.10 Tissue culture of fluorescent cells
MDA-MB-231 Cells expressing cytoplasmic green fluorescent protein and red
fluorescent protein-tagged Histone H2 were cultured in T-75 flasks and pas-
saged twice a week. Passaging was performed by firstly removing the medium
and washing the cell sheet with phosphate buﬀered saline (PBS, Thermo
Fisher Scientific). Cells were then incubated with 2ml of Trypsin (Thermo
Fisher Scientific) for 1-2 minutes at 37 . Flasks were struck in order to dis-
lodge the cell sheet prior to the addition of 3ml of medium (DMEM/F12,
Life Technologies) to inactivate the Trypsin. Cells were transferred to a new
flask and fresh medium added to give a final volume of 10ml.
4.10.11 RNAi screening
Silencer Select siRNAs (Thermo Fisher Scientific) were prepared by combin-
ing three individual siRNAs for each gene into an equimolar pool. Pooled
siRNAs were diluted in OptiMEM medium (Thermo Fisher Scientific) before
being combined 1:1 with transfection reagent (Lipofectamine RNAiMAX,
Thermo Fisher Scientific). The siRNA/reagent transfection mixture was in-
cubated at room temperature for 15 minutes before 5µL of mixture were
added to 384-well CellCarrier plates (PerkinElmer). Cells were diluted to
the required density in medium and 35µL added to each well to give a final
concentration of 10nM siRNA and 0.06µl of transfection reagent. The cells
were incubated with siRNAs for 48 hours, at 37 C, 5% CO2, 95% humidity
prior to wounding and analysis of cell velocity.
4.10.12 Cell velocity
Wound healing assays were performed by scratching the cells with a 96-well
pin tool to create wounds 2mm in thickness. Cells were imaged on the Opera
(PerkinElmer), at 37 C, 5% CO2, immediately after wounding and every
hour for 16 hours using a 10X objective with 2-pixel camera binning and 3
images captured per well. A 488nm excitation line with 450/50nm emission
filter was used for green fluorescent protein detection and a 561nm excita-
tion line with 585/40nm emission filter for red fluorescent protein detection.
Analysis of cell velocity was performed using the Bowhead algorithm (bow-
head.lindinglab.org). A p-value < 0.005 was used to delineate genes aﬀecting
velocity of wound closure.
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Table 4.3: Phosphopeptide regulation categories from the
GO biological processes Fig. 4.4 with a Fisher’s test odds
ratio >1 for the enrichment genes aﬀecting velocity were se-
lected and displayed. Genes may belong to multiple cate-
gories due to the phosphosites they represent.
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Table 4.4: Phosphopeptide regulation categories from the
GO cellular components Fig. 4.5 with a Fisher’s test odds
ratio >1 for the enrichment genes aﬀecting velocity were se-
lected and displayed. Genes may belong to multiple cate-
gories due to the phosphosites they represent.
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Epilogue
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Chapter 5
Summary and Perspectives
In this thesis, I have focused on two main projects utilizing mass spectrometry-
based proteomics to measure changes at the protein and phosphorylated pro-
tein levels. The first piece of work laid out in Chapter 3 looked at changes
upon expression of the PRKAR1A-RET fusion found in thyroid cancer. I
showed that the expression of this chromosomal rearrangement at endoge-
nous levels caused immortalized cells to acquire characteristics of transformed
cells. I was able to identify and propose several mechanisms by which the
protein-level eﬀects of this major genetic event might push cells toward trans-
formation and thus a state of increased malignancy.
The elucidation of the signaling network changes driving a more cancerous
phenotype will be key to better understand the functional eﬀects of this
relativelly understudies class of genetic alterations.While this work is only
a first step in terms of understanding the system-wide repercussions of a
single gene fusion, it is one of the few studies that have used high-throughput
proteomics to investigate its eﬀects. Given the enrichment of kinases as fusion
partners with oncogenic behavior, in the future it will be crucial to study
a much larger number of chromosomal rearrangements in order to uncover
trends in their modulation of protein networks and the cancer hallmarks they
thereby aﬀect.
In the second manuscript (Chapter 4) I induced a migratory signaling
response following wounding of triple negative breast cancer cells, and val-
idated this both in silico and experimentally. I also identified numerous
regulated protein phosphorylation sites that have not yet been linked to mi-
gration. Follow-up experiments are already in place for the validation of a
subset of these sites, as well as to gain a deeper understanding of the spatial
dynamics of very early signaling upon wounding. In terms of the application
of these findings in the clinic, it is interesting that there are currently no
available treatments targeting specific phosphorylation sites. This is likely
due to the diﬃculty in developing drugs targeted to one site. We propose to
develop antibody fragments toward specific phosphorylation sites and to then
inhibit a site alone or in conjunction with other sites. It is possible that this
could be suﬃcient to aﬀect signal transduction and therefore to halt disease
initiation or progression. This strategy would diﬀerentiate itself from kinase
inhibitors, which generally target the active site of kinases. During this work,
it became very apparent that the number of functionally annotated sites is
limited. Moving forward it will be essential that studies investigating signal-
ing link sites to biological functions, rather than simply listing these if they
are to be a resource to the community. For instance, in the work performed
in this thesis, we suggest that the modulated phosphosites have a role in the
induction of migration.
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The work described herein underscores the importance of studying sys-
tems from a protein perspective within the field of cancer research. Indeed,
as alluded to throughout the thesis, there is a discrepancy between the ap-
proach of determining drug targets and the way in which drugs function in
vivo. For the most part, anti-cancer drugs typically exert their eﬀect by in-
teracting with a protein, thereby aﬀecting the dysregulated behaviour of the
malignant cell. Interfering with processes by targeting proteins is a powerful
approach, given that proteins are the eﬀectors of cell behavior and directly af-
fect the very phenotypes that are to be targeted. Is it curious then that drug
targets are often selected based on findings from genomic or transcriptomic
data. While this makes sense from a historical perspective, it is perhaps now
time to turn the tables.
